

7. Davies GR, et al. (1994) Relationship between infective load of *Helicobacter pylori* and reactive oxygen metabolite production in antral mucosa. *Scand J Gastroenterol* 29: 419–424.
8. Davies GR, et al. (1994) *Helicobacter pylori* stimulates antral mucosal reactive oxygen metabolite production in vivo. *Gut* 35:179–185.
9. Mannick EE, et al. (1996) Inducible nitric oxide synthase, nitrotyrosine, and apoptosis in *Helicobacter pylori* gastritis: Effect of antibiotics and antioxidants. *Cancer Res* 56: 3238–3243.
10. Meira LB, et al. (2008) DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. *J Clin Invest* 118:2516–2525.
11. Nair J, et al. (2006) Increased etheno-DNA adducts in affected tissues of patients suffering from Crohn's disease, ulcerative colitis, and chronic pancreatitis. *Antioxid Redox Signal* 8:1003–1010.
12. Zhuang JC, Lin C, Lin D, Wogan GN (1998) Mutagenesis associated with nitric oxide production in macrophages. *Proc Natl Acad Sci USA* 95:8286–8291.
13. Sato Y, et al. (2006) IL-10 deficiency leads to somatic mutations in a model of IBD. *Carcinogenesis* 27:1068–1073.
14. Bartsch H, Nair J (2004) Oxidative stress and lipid peroxidation-derived DNA-lesions in inflammation driven carcinogenesis. *Cancer Detect Prev* 28:385–391.
15. Nair U, Bartsch H, Nair J (2007) Lipid peroxidation-induced DNA damage in cancer-prone inflammatory diseases: a review of published adduct types and levels in humans. *Free Radic Biol Med* 43:1109–1120.
16. Kang JM, Iovine NM, Blaser MJ (2006) A paradigm for direct stress-induced mutation in prokaryotes. *FASEB J* 20:2476–2485.
17. Crabtree JE, Ferrero RL, Kusters JG (2002) The mouse colonizing *Helicobacter pylori* strain 551 may lack a functional cag pathogenicity island. *Helicobacter* 7:139–140, author reply 140–141.
18. Lee A, Mitchell H, O'Rourke J (2002) The mouse colonizing *Helicobacter pylori* strain 551 may lack a functional cag pathogenicity island: Response. *Helicobacter* 7:140–141.
19. Miyazawa M, et al. (2003) Suppressed apoptosis in the inflamed gastric mucosa of *Helicobacter pylori*-colonized iNOS-knockout mice. *Free Radic Biol Med* 34:1621–1630.
20. Jang J, et al. (2003) Malgun (clear) cell change in *Helicobacter pylori* gastritis reflects epithelial genomic damage and repair. *Am J Pathol* 162:1203–1211.
21. Lee H, et al. (2000) "Malgun" (clear) cell change of gastric epithelium in chronic *Helicobacter pylori* gastritis. *Pathol Res Pract* 196:541–551.
22. Touati E, et al. (2003) Chronic *Helicobacter pylori* infections induce gastric mutations in mice. *Gastroenterology* 124:1408–1419.
23. Jenks PJ, Jeremy AH, Robinson PA, Walker MM, Crabtree JE (2003) Long-term infection with *Helicobacter felis* and inactivation of the tumour suppressor gene p53 cumulatively enhance the gastric mutation frequency in Big Blue transgenic mice. *J Pathol* 201:596–602.
24. Nohmi T, et al. (1996) A new transgenic mouse mutagenesis test system using Spi- and 6-thioguanine selections. *Environ Mol Mutagen* 28:465–470.
25. Ihrig M, Whary MT, Dangler CA, Fox JG (2005) Gastric *Helicobacter* infection induces a Th2 phenotype but does not elevate serum cholesterol in mice lacking inducible nitric oxide synthase. *Infect Immun* 73:1664–1670.
26. Lee CW, et al. (2008) *Helicobacter pylori* eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. *Cancer Res* 68:3540–3548.
27. Fox JG, et al. (2000) Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces *Helicobacter*-induced gastric atrophy. *Nat Med* 6:536–542.
28. De Bont R, van Larebeke N (2004) Endogenous DNA damage in humans: A review of quantitative data. *Mutagenesis* 19:169–185.
29. Burney S, Caulfield JL, Niles JC, Wishnok JS, Tannenbaum SR (1999) The chemistry of DNA damage from nitric oxide and peroxynitrite. *Mutat Res* 424:37–49.
30. Kadlubar FF, et al. (1998) Comparison of DNA adduct levels associated with oxidative stress in human pancreas. *Mutat Res* 405:125–133.
31. Pandya GA, Moriya M (1996) 1, N<sup>6</sup>-ethenodeoxyadenosine, a DNA adduct highly mutagenic in mammalian cells. *Biochemistry* 35:11487–11492.
32. Ambs S, et al. (1999) Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. *J Natl Cancer Inst* 91:86–88.
33. Kim MY, Wogan GN (2006) Mutagenesis of the supF gene of pSP189 replicating in AD293 cells cocultivated with activated macrophages: roles of nitric oxide and reactive oxygen species. *Chem Res Toxicol* 19:1483–1491.
34. Dedon PC, Plastaras JP, Rouzer CA, Marnett LJ (1998) Indirect mutagenesis by oxidative DNA damage: formation of the pyrimidopyrimidone adduct of deoxyguanosine by base propanal. *Proc Natl Acad Sci USA* 95:11113–11116.
35. Jackson AL, Loeb LA (2001) The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. *Mutat Res* 477:7–21.
36. Wood ML, Esteve A, Morningstar ML, Kuziemko GM, Essigmann JM (1992) Genetic effects of oxidative DNA damage: comparative mutagenesis of 7,8-dihydro-8-oxoguanine and 7,8-dihydro-8-oxoadenine in *Escherichia coli*. *Nucleic Acids Res* 20: 6023–6032.
37. Pang B, et al. (2007) Lipid peroxidation dominates the chemistry of DNA adduct formation in a mouse model of inflammation. *Carcinogenesis* 28:1807–1813.
38. Masumura K, et al. (2003) Low dose genotoxicity of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) in gpt delta transgenic mice. *Mutat Res* 541:91–102.
39. Masumura K, et al. (2000) Characterization of mutations induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in the colon of gpt delta transgenic mouse: novel G:C deletions beside runs of identical bases. *Carcinogenesis* 21:2049–2056.
40. Balkwill F, Coussens LM (2004) Cancer: An inflammatory link. *Nature* 431:405–406.
41. Clevers H (2004) At the crossroads of inflammation and cancer. *Cell* 118:671–674.
42. Court M, Robinson PA, Dixon MF, Jeremy AH, Crabtree JE (2003) The effect of gender on *Helicobacter felis*-mediated gastritis, epithelial cell proliferation, and apoptosis in the mouse model. *J Pathol* 201:303–311.
43. Fox JG, et al. (2002) Germ-line p53-targeted disruption inhibits *Helicobacter*-induced premalignant lesions and invasive gastric carcinoma through down-regulation of Th1 proinflammatory responses. *Cancer Res* 62:696–702.
44. Lee A, Fox JG, Otto G, Murphy J (1990) A small animal model of human *Helicobacter pylori* active chronic gastritis. *Gastroenterology* 99:1315–1323.
45. Taylor NS, et al. (1995) Long-term colonization with single and multiple strains of *Helicobacter pylori* assessed by DNA fingerprinting. *J Clin Microbiol* 33:918–923.
46. Lemke LB, et al. (2009) Concurrent *Helicobacter bilis* infection in C57BL/6 mice attenuates proinflammatory *H. pylori*-induced gastric pathology. *Infect Immun* 77: 2147–2158.
47. Crabtree JE, et al. (2004) Gastric mucosal cytokine and epithelial cell responses to *Helicobacter pylori* infection in Mongolian gerbils. *J Pathol* 202:197–207.
48. Fox JG, et al. (2003) Host and microbial constituents influence *Helicobacter pylori*-induced cancer in a murine model of hypergastrinemia. *Gastroenterology* 124:1879–1890.
49. Bamford KB, et al. (1998) Lymphocytes in the human gastric mucosa during *Helicobacter pylori* have a T helper cell 1 phenotype. *Gastroenterology* 114:482–492.
50. Mohammadi M, Czinn S, Redline R, Nedrud J (1996) *Helicobacter*-specific cell-mediated immune responses display a predominant Th1 phenotype and promote a delayed-type hypersensitivity response in the stomachs of mice. *J Immunol* 156: 4729–4738.
51. Sakagami T, et al. (1996) Atrophic gastric changes in both *Helicobacter felis* and *Helicobacter pylori* infected mice are host dependent and separate from antral gastritis. *Gut* 39:639–648.
52. Lee CW, et al. (2007) Wild-type and interleukin-10-deficient regulatory T cells reduce effector T-cell-mediated gastroduodenitis in Rag2<sup>-/-</sup> mice, but only wild-type regulatory T cells suppress *Helicobacter pylori* gastritis. *Infect Immun* 75:2699–2707.
53. Kao JY, et al. (2010) *Helicobacter pylori* immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. *Gastroenterology* 138:1046–1054.
54. Xu S, Cao X (2010) Interleukin-17 and its expanding biological functions. *Cell Mol Immunol* 7:164–174.
55. Rogers AB, et al. (2005) *Helicobacter pylori* but not high salt induces gastric intraepithelial neoplasia in B6129 mice. *Cancer Res* 65:10709–10715.
56. Masumura K, et al. (1999) Spectra of gpt mutations in ethylnitrosourea-treated and untreated transgenic mice. *Environ Mol Mutagen* 34:1–8.
57. Nüesch J, Schümperli D (1984) Structural and functional organization of the gpt gene region of *Escherichia coli*. *Gene* 32:243–249.
58. Kim MY, Dong M, Dedon PC, Wogan GN (2005) Effects of peroxynitrite dose and dose rate on DNA damage and mutation in the supF shuttle vector. *Chem Res Toxicol* 18: 76–86.

## Research Article

Antigenotoxic Effects of *p53* on Spontaneous and Ultraviolet Light B–Induced Deletions in the Epidermis of *gpt* Delta Transgenic Mice

Kenichi Masumura,<sup>1</sup> Yasuteru Sakamoto,<sup>1</sup> Megumi Ikeda,<sup>1,2</sup> Yasuo Asami,<sup>1</sup>  
Tetsuya Tsukamoto,<sup>3</sup> Hironobu Ikehata,<sup>4</sup> Yuichi Kuroiwa,<sup>5</sup>  
Takashi Umemura,<sup>5</sup> Akiyoshi Nishikawa,<sup>5</sup> Masae Tatematsu,<sup>3</sup>  
Tetsuya Ono,<sup>4</sup> and Takehiko Nohmi<sup>1\*</sup>

<sup>1</sup>Division of Genetics and Mutagenesis, National Institute of Health Sciences, Tokyo, Japan

<sup>2</sup>School of Nutrition and Dietetics, Kanagawa University of Human Services, Kanagawa, Japan

<sup>3</sup>Division of Oncological Pathology, Aichi Cancer Center Research Institute, Nagoya, Japan

<sup>4</sup>Department of Cell Biology, Tohoku University Graduate School of Medicine, Sendai, Japan

<sup>5</sup>Division of Pathology, National Institute of Health Sciences, Tokyo, Japan

Tumor development in the skin may be a multistep process where multiple genetic alterations occur successively. The *p53* gene is involved in genome stability and thus is referred to as “the guardian of the genome.” To better understand the antigenotoxic effects of *p53* in ultraviolet light B (UVB)-induced mutagenesis, mutations were measured in the epidermis of UVB-irradiated *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> *gpt* delta mice. In the mouse model, point mutations and deletions are separately identified by the *gpt* and Spi<sup>-</sup> assays, respectively. The mice were exposed to UVB at single doses of 0.5, 1.0, or 2.0 kJ/m<sup>2</sup>. The mutant frequencies (MFs) were determined 4 weeks after the irradiation. All doses of UVB irradiation enhanced *gpt* MFs by about 10 times than that of unirradiated mice. There were no significant differences in *gpt* MFs and the mutation

spectra between *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> mice. The predominant mutations induced by UVB irradiation were G:C to A:T transitions at dipyrimidines. In contrast, in unirradiated *p53*<sup>-/-</sup> mice, the frequencies of Spi<sup>-</sup> large deletions of more than 1 kb and complex-type deletions with rearrangements were significantly higher than those of the Spi<sup>-</sup> large deletions in *p53*<sup>+/+</sup> counterparts. The specific Spi<sup>-</sup> mutation frequency of more than 1 kb deletions and complex types increased in a dose-dependent manner in the *p53*<sup>+/+</sup> mice. However, no increase of such large deletions was observed in irradiated *p53*<sup>-/-</sup> mice. These results suggest that the antigenotoxic effects of *p53* may be specific to deletions and complex-type mutations induced by double-strand breaks in DNA. Environ. Mol. Mutagen. 52:244–252, 2011. © 2010 Wiley-Liss, Inc.

**Key words:** Spi; deletion mutations; dipyrimidines; mutation frequency

## INTRODUCTION

The *p53* gene is involved in various aspects of genome stability and thus is referred to as “the guardian of the genome.” Several strains of transgenic mice were developed in which a major part of *p53* was deleted [Donehower et al., 1992; Tsukada et al., 1993; Jacks et al., 1994; Purdie et al., 1994], and each of these knockout strains has a propensity to develop thymic lymphoma at an early stage. However, no significant difference in spontaneous *lacI* mutant frequencies (MFs) has been reported between *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> mice [Nishino et al., 1995; Buettner et al., 1996]. In addition, *lacI* MFs induced after exposure to 4-nitroquinoline 1-oxide (4-NQO) are not significantly different between *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> mice [Sands et al., 1995]. Because the *lacI* transgene preferentially detects point mutations [Nishino et al., 1995], it was suggested that *p53* deficiency did not affect accumulation of

Grant sponsor: Ministry of Education, Sports, Culture, Science and Technology (MEXT); Grant number: Crossover Research and basic research (18201010); Grant sponsor: Ministry of Health, Labour and Welfare (MHLW); Grant number: H21-Food-General-009; Grants-in-Aid for Cancer Research (20S-8); Grant sponsor: Japan Health Science Foundation; Grant number: KHB1007; Grant sponsor: public hazard research from the Ministry of Environment, Japan.

\*Correspondence to: Dr. Takehiko Nohmi, Division of Genetics and Mutagenesis, National Institute of Health Sciences, 1-18-1 Kamiyoga Setagaya-ku, Tokyo, Japan. E-mail: nohmi@nihs.go.jp

Received 21 November 2009; provisionally accepted 24 May 2010; and in final form 25 May 2010

DOI 10.1002/em.20610

Published online 25 August 2010 in Wiley Online Library (wileyonlinelibrary.com).

point mutations in vivo. However, it remains uncertain, whether *p53* deficiency affects other types of mutations or chromosome aberrations. In fact, a study with the endogenous *aprt* gene, which detects loss of heterozygosity (LOH) induced by chromosome aberrations and point mutations, showed that frequencies of chromosome aberrations were significantly increased in *p53*<sup>-/-</sup> mice compared with *p53*<sup>+/+</sup> [Shao et al., 2000]. Another study, using the endogenous *p*<sup>um</sup> reversion mutation assay, suggested that *p53* was involved in X-ray-induced intrachromosomal recombination [Aubrecht et al., 1999]. Loss of *p53* function was associated with an increase in the frequency of LOH within the *tk* gene in TK6 human cells in vitro [Morris, 2002]. These studies suggest that the effect of *p53* loss may be influential in deletions and/or rearrangement-type mutations induced by DNA double-strand breaks (DSB).

To further investigate the effects of *p53* on point mutations and deletions in vivo, we analyzed mutations in the epidermis of *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> *gpt* delta mice exposed to ultraviolet light B (UVB) irradiation. In this mouse model, point mutations and deletions are separately identified by the *gpt* and Spi<sup>-</sup> assays [Nohmi et al., 1996, 2000; Nohmi, 2007]. UVB is responsible for most carcinogenic effects of sun exposure. The sunlight-induced mutation spectrum is highly UV-specific, quite similar to that induced by UVB [Ikehata et al., 2004]. UVB irradiation induces not only point mutations, such as G:C to A:T transitions, but also deletions of more than 1 kb in the epidermis of *gpt* delta mice [Horiguchi et al., 1999, 2001]. In this study, we demonstrated that Spi<sup>-</sup> MFs in unirradiated *p53*<sup>-/-</sup> mice were significantly higher than that in *p53*<sup>+/+</sup> counterparts. In the *p53*<sup>-/-</sup> background, large deletions greater than 1 kb in size and complex-type rearrangements were much more frequently observed, compared with the *p53*<sup>+/+</sup> counterparts. Interestingly, the specific Spi<sup>-</sup> mutation frequency of the large deletions and complex types increased in a dose-dependent manner in the *p53*<sup>+/+</sup> mice. However, no increase in frequencies of such large deletions was observed in irradiated *p53*<sup>-/-</sup> mice. There were no significant differences in the *gpt* MF and spectra between *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> mice regardless of the presence or the absence of UVB irradiation. The results suggest that *p53* affects the induction of deletions and rearrangements but not the induction or accumulation of point mutations in vivo.

## MATERIALS AND METHODS

### UVB Irradiation of *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> *gpt* Delta Mice

Homozygous *gpt* delta transgenic mice of C57BL/6J genetic background [Nohmi et al., 2000] were mated with *p53*<sup>+/-</sup> mice of C57BL/6J background [Tsukada et al., 1993], and *p53*<sup>+/-</sup> *gpt* delta mice were obtained. We obtained *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> *gpt* delta mice by intercrossing *p53*<sup>+/-</sup> *gpt* delta mice. Genotypes of the *p53* and *gpt* genes were examined by polymerase chain reaction (PCR) as described in the study of Tsukada et al. (1993), Nohmi et al. (1996). In this study, male *p53*<sup>+/+</sup> and

*p53*<sup>-/-</sup> *gpt* delta mice (6–10 weeks old) were used. The experimental protocol described in the following sections was approved by the Animal Care and Utilization Committee of the National Institute of Health Sciences. For UVB irradiation of the skin, the hair on the back was removed using a clipper and hair removing cream under anesthesia. Four days later, the mice were exposed to UVB at a single dose of 0.5, 1.0, or 2.0 kJ/m<sup>2</sup> (0.3 kJ/m<sup>2</sup>/min) under anesthesia. The UV source was a model UVM-57 (UVP, Upland, CA). Dose rate was measured by a UVX-31 Radiometer (UVP, Upland, CA). Irradiation was performed in a CHROMATO-VUE<sup>®</sup> CABINET model CC-10 (UVP, Upland, CA). Four mice were used in each group. They were sacrificed 4 weeks later and the back skin was collected and stored at -80°C. The epidermis was separated from the skin using thermolysin treatment and genomic DNA was extracted by the phenol/chloroform/isoamyl alcohol method [Ikehata et al., 2001]. Lambda EG10 phages were rescued from the genomic DNA by in vitro packaging reactions using Transpack<sup>®</sup> packaging extract (Stratagene, La Jolla, CA) and used for the following mutation assays.

### Mutation Assay and Sequencing Analysis

The *gpt* mutation assay was performed as described previously [Nohmi et al., 2000]. The rescued phages were used to infect *E. coli* strain YG6020 expressing Cre recombinase to convert the transgene to plasmid. Infected cells were mixed with molten soft agar and poured onto agar plates containing chloramphenicol (Cm) and 6-thioguanine (6-TG). The plates were incubated for 3 days at 37°C to select for colonies harboring the plasmid carrying the mutated *gpt* gene. Infected cells were also poured on plates containing Cm without 6-TG to determine the number of rescued plasmids. The *gpt* MF was calculated as described previously [Nohmi et al., 2000]. The selected 6-TG-resistant mutants were cultured and collected. A 739-bp DNA fragment containing the mutated *gpt* gene was amplified by PCR [Nohmi et al., 2000]. DNA sequencing of the *gpt* gene was performed with BigDye<sup>®</sup> Terminator Cycle Sequencing Ready Reaction (Applied Biosystems, Foster City, CA) on a ABI PRISM<sup>®</sup> 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA). The sequencing primer was the *gpt*A2 primer (5'-TCTCGCGCAACCTATTTC3'). Clonally corrected mutation spectra were estimated, that is, counting the same mutation from the same animal as one mutation.

The Spi<sup>-</sup> mutation assay was performed as described previously [Nohmi et al., 2000] with some modifications. We added 10 mM MgSO<sub>4</sub> to both agar plates and soft agar to improve the detection efficiency of Spi<sup>-</sup> plaques, as described previously [Shibata et al., 2003]. The rescued phages from the genomic DNA of *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> *gpt* delta mice were used to infect *E. coli* XL1-Blue MRA (P2). Infected cells were mixed with molten soft agar, poured onto lambda-trypticase agar plates, and incubated at 37°C. The plaques detected on the plates (Spi<sup>-</sup> candidates) were suspended in 50 µl of SM buffer. The suspension was spotted on two types of plates, spread with either XL1-Blue MRA (P2) or the WL95 (P2) strain. The plates were incubated overnight at 37°C. The number of mutants that made clear spots on both strains was counted as confirmed Spi<sup>-</sup> mutants. The Spi<sup>-</sup> MF was calculated as described previously [Nohmi et al., 2000]. The MFs were corrected for potential clonal expansion. The lysates of the Spi<sup>-</sup> mutants were obtained by infection of *E. coli* LE392 with the recovered Spi<sup>-</sup> mutants. The lambda DNA was extracted from the lysates with the Quantum Prep<sup>®</sup> AquaPure<sup>™</sup> Genomic DNA Isolation Kit (BIO-RAD, Hercules, CA). The lysate and extracted DNA were used as templates for PCR analysis to determine the deleted regions. The DNA fragments containing the deletions which were amplified by PCR using primers 001–002 (5 kb in length), 005–012 (14 kb), or 005–006 (21 kb), followed by sequencing analysis of the PCR products. The PCR primers were:

- primer 001 (5'-CTCTCCTTGTATGCGAATGCCAGC-3'),
- primer 002 (5'-GGAGTAATTATGCGGAACAGAATCATGC-3'),




Fig. 1. *gpt* MFs in the epidermis of UVB-irradiated *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> *gpt* delta mice. \* Denotes  $P < 0.05$  ( $n = 4$ ) in Dunnett test (for *p53*<sup>+/+</sup>) or Kruskal–Wallis test (for *p53*<sup>-/-</sup>) comparing the MFs of UVB-irradiated versus the corresponding unirradiated mice. Vertical bars show the standard deviations with mice as the unit of comparison.

- primer 005 (5'-CGTGGTCTGAGTGTGTTACAGAGG-3'),
- primer 006 (5'-GTTATGCGTTGTTCCATACAACCTCC-3'), and
- primer 012 (5'-CGGTCGAGGGACCTAATAACTTCG-3').

Sequence changes within and outside of the *gam/redBA* genes were identified by DNA sequencing analysis. The appropriate primers for DNA sequencing were selected based on the results of PCR analysis. The entire sequence of lambda EG10 is available at <http://dgm2alpha.nihs.go.jp>.

### Statistical Analysis

All data are expressed as mean  $\pm$  SD. Statistical analyses were performed by analysis of variance followed by parametric (Dunnett) or non-parametric (Kruskal–Wallis) test to compare between two groups. Cochran–Armitage trend test was applied for significance of dose-dependent increase as noted in a detailed review of transgenic rodent mutation assays [Lambert et al., 2005]. A comparison of mutational spectra was performed using Adams–Skopek test [Adams and Skopek, 1987; Cariello et al., 1994]. A  $P$  value less than 0.05 denoted a statistically significant difference.

## RESULTS

### Increased *gpt* MFs in the Epidermis of UVB-Irradiated *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> Mice

The *gpt* MFs in the epidermis of *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> *gpt* delta mice were significantly increased by UVB irradiation at 0.5, 1.0, or 2.0 kJ/m<sup>2</sup> compared with unirradiated mice (Fig. 1). In *p53*<sup>+/+</sup> mice, *gpt* MFs of the irradiated groups were 85.0–90.9  $\times 10^{-6}$ , which were similar to those of the irradiated groups of the *p53*<sup>-/-</sup> mice (84.9–92.6  $\times 10^{-6}$ ). These values were 9–15 times higher than those of unirradiated mice (9.6  $\times 10^{-6}$  and 6.2  $\times 10^{-6}$ , respectively, for *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> mice). The *gpt* MFs in the unirradiated groups were not significantly different between *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> mice. There were no dose-dependent increases in *gpt* MFs regardless of the

*p53* status. This may suggest that *gpt* MFs in the epidermis were saturated at UVB doses greater than 0.5 kJ/m<sup>2</sup>.

### Induction of G:C to A:T Transitions at Dipyrimidines in the Epidermis of UVB-Irradiated *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> Mice

To investigate the type of mutations induced by UVB irradiation, we determined the *gpt* mutation spectra in the epidermis of *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> *gpt* delta mice (Tables I and II). In UVB-irradiated *p53*<sup>+/+</sup> mice, G:C to A:T transitions were the predominant mutations, i.e., 78% (28/36), 76% (22/29), and 74% (28/38) at 0.5, 1.0, and 2.0 kJ/m<sup>2</sup>, respectively. Most of the G:C to A:T transitions were observed on the 3' side of the dipyrimidines that were 5'-CC-3' and 5'-TC-3', that is, 93% (26/28), 95% (21/22), and 86% (24/28) of G:C to A:T transitions for 0.5, 1.0, and 2.0 kJ/m<sup>2</sup>, respectively. No significant differences in the *gpt* mutation spectra were observed between UVB-irradiated groups. In UVB-irradiated *p53*<sup>-/-</sup> mice, G:C to A:T transitions were 65% (22/34), 81% (29/36), and 69% (20/28) of mutations for 0.5, 1.0, and 2.0 kJ/m<sup>2</sup>, respectively. The G:C to A:T transitions observed on the 3' side of the dipyrimidines, 5'-CC-3' and 5'-TC-3', were 91% (20/22), 83% (24/29), and 95% (19/20) of G:C to A:T transitions for 0.5, 1.0, and 2.0 kJ/m<sup>2</sup>, respectively. The tandem base substitution, 5'-CC-3' to 5'-TT-3', was observed in *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> mice. The characteristics of the *gpt* mutation spectra were similar between irradiated *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> mice ( $P = 0.91$ , Adams–Skopek test). In untreated mice, base substitutions such as G:C to A:T, G:C to T:A, and A:T to T:A were observed in both *p53*<sup>+/+</sup> (86%, 32/37) and *p53*<sup>-/-</sup> (89%, 16/18) mice.

### High-Spontaneous Spi<sup>-</sup> MFs in *p53*<sup>-/-</sup> Mice

To investigate the induction of deletions, Spi<sup>-</sup> MFs in the epidermis of *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> *gpt* delta mice were determined. In *p53*<sup>+/+</sup> mice, Spi<sup>-</sup> MFs were significantly increased by UVB irradiation at 1.0 or 2.0 kJ/m<sup>2</sup> compared with those of unirradiated mice (Table III). The Spi<sup>-</sup> MFs were increased four times for the 1.0 and 2.0 kJ/m<sup>2</sup> doses compared with the control level. In *p53*<sup>-/-</sup> mice, the Spi<sup>-</sup> MF of unirradiated mice was 4.91  $\times 10^{-6}$ , which was 2.5 times higher than that of *p53*<sup>+/+</sup> mice (1.96  $\times 10^{-6}$ ). In the UVB-irradiated groups, Spi<sup>-</sup> MFs were 1.2- to 1.7-fold higher but not significantly different from those of the unirradiated mice.

### Characteristics of Spi<sup>-</sup> Large Deletions in *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> Mice

To characterize the UVB-induced deletion mutations in more detail, the Spi<sup>-</sup> mutants rescued from the epidermis were subjected to PCR analysis. The Spi<sup>-</sup> mutants that had the deletions with the sizes more than 1 kb were selected and analyzed by DNA sequencing. The specific



TABLE I. *gpt* Mutation Spectra in the Epidermis of UVB-Irradiated *p53*<sup>+/+</sup> *gpt* Delta Mice

	0 kJ/m <sup>2</sup>		0.5 kJ/m <sup>2</sup>		1.0 kJ/m <sup>2</sup>		2.0 kJ/m <sup>2</sup>	
	No.	MF <sup>a</sup> (×10 <sup>-6</sup> )	No.	MF (×10 <sup>-6</sup> )	No.	MF (×10 <sup>-6</sup> )	No.	MF (×10 <sup>-6</sup> )
Base substitution								
Transition								
G:C → A:T	24 (6)	6.2	28 (3)	66.1	22 (2)	66.0	28 (3)	66.9
A:T → G:C	1	0.3	0	0.0	2	6.0	1	2.4
Transversion								
G:C → T:A	6	1.6	2	4.7	0	0.0	2	4.8
G:C → C:G	1	0.3	1	2.4	0	0.0	0	0.0
A:T → T:A	2	0.5	3	7.1	3	9.0	2	4.8
A:T → C:G	0	0.0	0	0.0	1	3.0	1	2.4
Tandem base substitution	0	0.0	1	2.4	1	3.0	3	7.2
Deletion								
-1 bp	0		0		0		1	
>2 bp	1		0		0		0	
Insertion	0	0.5	0	0.0	0	0.0	0	0.0
Others <sup>b</sup>	0	0.0	1	2.4	0	0.0	0	0.0
Total no.	37	9.6	36	85.0	29	87.0	38	90.9

<sup>a</sup>MFs are calculated by dividing total MF by the ratio of each type of mutations.

<sup>b</sup>Others: TAA to AAG.

( )=CpG sites.

TABLE II. *gpt* Mutation Spectra in the Epidermis of UVB-Irradiated *p53*<sup>-/-</sup> *gpt* Delta Mice

	0 kJ/m <sup>2</sup>		0.5 kJ/m <sup>2</sup>		1.0 kJ/m <sup>2</sup>		2.0 kJ/m <sup>2</sup>	
	No.	MF <sup>a</sup> (×10 <sup>-6</sup> )	No.	MF (×10 <sup>-6</sup> )	No.	MF (×10 <sup>-6</sup> )	No.	MF (×10 <sup>-6</sup> )
Base substitution								
Transition								
G:C → A:T	13 (1)	4.5	22 (2)	54.9	29 (4)	74.6	20	63.1
A:T → G:C	0	0.0	4	10.0	1	2.6	0	0.0
Transversion								
G:C → T:A	1	0.3	0	0.0	0	0.0	4	12.6
G:C → C:G	0	0.0	0	0.0	1	2.6	0	0.0
A:T → T:A	2	0.7	2	5.0	1	2.6	2	6.3
A:T → C:G	0	0.0	2	5.0	1	2.6	0	0.0
Tandem base substitution	2	0.7	3	7.5	1	2.6	0	0.0
Deletion								
-1 bp	0		0		1		1	
>2 bp	0		0		0		0	
Insertion	0	0.0	1	2.5	0	0.0	1	3.2
Others <sup>b</sup>	0	0.0	0	0.0	1	2.6	1	3.2
Total no.	18	6.2	34	84.9	36	92.6	28	91.4

<sup>a</sup>MFs are calculated by dividing total MF by the ratio of each type of mutations.

<sup>b</sup>Others = TCA to TT, CCT to CA.

( )=CpG sites.

*Spi*<sup>-</sup> mutation frequencies of large deletions (greater than 1 kb) and complex (deletion with rearrangement) types are shown in Figure 2. In this study, "complex types" were defined as deletion mutants whose junctions were unable to be identified by PCR and sequencing analyses because of the complex rearrangements. In the *p53*<sup>+/+</sup> mice, the specific *Spi*<sup>-</sup> mutation frequency increased in a dose-dependent manner ( $P = 0.01$  in Cochran-Armitage trend test), and was about five times higher at 2.0 kJ/m<sup>2</sup> ( $0.93 \times 10^{-6}$ ) than that of the unirradiated mice ( $0.17 \times 10^{-6}$ ). On the other hand, the specific *Spi*<sup>-</sup> mutation fre-

quency of large deletions in unirradiated *p53*<sup>-/-</sup> mice was significantly higher than that of unirradiated *p53*<sup>+/+</sup> mice ( $1.58 \times 10^{-6}$  compared with  $0.17 \times 10^{-6}$ ,  $P = 0.04$  in Dunnett test). No significant increase in the specific *Spi*<sup>-</sup> mutation frequency of large deletions was observed in three irradiated groups of *p53*<sup>-/-</sup> mice. We identified the size and junctions of 39 *Spi*<sup>-</sup> deletions and summarized the nature of the large deletions (greater than 1 kb) recovered from both *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> mice (Fig. 3). The largest deletion size was -7,094 bp. The identical mutation was recovered multiple times from the

TABLE III. Spi<sup>-</sup> Mutant Frequency in the Epidermis of UVB-Irradiated *gpt* Delta Mice

UVB (kJ/m <sup>2</sup> )	Animal ID	Total population	No. of mutants	MF (× 10 <sup>-6</sup> )	Average	SD
<i>p53<sup>+/+</sup></i>						
0.0	101	1,569,000	5	3.19	1.96	0.89
	102	3,411,000	4	1.17		
	103	1,506,000	3	1.99		
	104	1,361,500	2	1.47		
0.5	201	1,389,000	5	3.60	4.14	1.79
	202	1,629,000	11	6.75		
	203	2,250,000	6	2.67		
	204	1,131,000	4	3.54		
1.0	301	1,907,000	6	3.15	7.31*	3.98
	302	1,421,500	18	12.66		
	303	1,158,000	7	6.04		
	304	1,083,000	8	7.39		
2.0	401	1,038,000	9	8.67	8.24**	0.45
	402	1,800,000	14	7.78		
	403	1,569,000	13	8.29		
	404			ND		
<i>p53<sup>-/-</sup></i>						
0.0	501	1,735,000	10	5.76	4.91	2.74
	502	714,000	6	8.40		
	503	1,608,000	4	2.49		
	504	1,002,000	3	2.99		
0.5	601	783,000	9	11.49	8.30	2.46
	602	1,005,000	8	7.96		
	603	1,995,000	11	5.51		
	604	1,461,000	12	8.21		
1.0	701	1,344,000	12	8.93	6.04	2.16
	702	1,551,000	9	5.80		
	703	2,442,000	9	3.69		
	704	1,743,000	10	5.74		
2.0	801	1,275,000	15	11.76	8.06	3.47
	803	1,209,000	6	4.96		
	804	1,365,000	14	10.26		
	805	3,048,000	16	5.25		

\*Denotes  $P < 0.05$  in Dunnett test comparing the MFs of UVB-irradiated versus the corresponding unirradiated mice.

\*\*Denotes  $P < 0.01$ .




Fig. 2. Specific Spi<sup>-</sup> mutation frequencies of large deletions (greater than 1 kb) and complex-type deletions in the epidermis of UVB-irradiated *p53<sup>+/+</sup>* and *p53<sup>-/-</sup>* *gpt* delta mice. \* Denotes  $P < 0.05$  ( $n = 4$ ) for the MFs of *p53<sup>-/-</sup>* mice versus the corresponding *p53<sup>+/+</sup>* mice (Dunnett test). Vertical bars show the standard deviations with mice as the unit of comparison.

same group: -3,979 bp deletions were recovered from three of four mice for each group (0.5, 1.0, or 2.0 kJ/m<sup>2</sup>) of UVB-irradiated *p53<sup>-/-</sup>* mice. The identical complex type was recovered from four mice with *p53<sup>-/-</sup>* background irradiated with 1.0 kJ/m<sup>2</sup> UVB.

## DISCUSSION

The tumor suppressor gene *p53* plays important roles in the maintenance of genome integrity. To characterize the antimutagenic potential of *p53* in skin carcinogenesis, where *p53* is frequently inactivated by sunlight [Brash et al., 1991], we compared the frequencies and spectra of *gpt* and Spi<sup>-</sup> mutations in *p53<sup>+/+</sup>* and *p53<sup>-/-</sup>* *gpt* delta mice. The *gpt* MFs in the epidermis of *p53<sup>+/+</sup>* and *p53<sup>-/-</sup>* mice were significantly increased by UVB irradiation at 0.5, 1.0, or 2.0 kJ/m<sup>2</sup> compared with those of unirradiated mice (Fig. 1). However, there were no substantial differences in *gpt* MF between *p53<sup>+/+</sup>* and *p53<sup>-/-</sup>* mice. The *gpt* mutation spectra were also similar between *p53<sup>+/+</sup>* and *p53<sup>-/-</sup>* mice (Tables




Fig. 3. Molecular nature of large deletions recovered from the epidermis of UVB-irradiated *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> *gpt* delta mice. A partial genetic map of the lambda EG10 transgene including the *gam* and *redBA* target region of Spi<sup>-</sup> selection is shown in the upper part. Horizontal gray bars represent the deleted regions of mutants. Junctions are indicated as spaces between left and right sequences. Short homologous sequences in the junctions of the mutants are underlined. Underlined, italicized sequences are inserted sequences. \*The identical independent mutant was recovered multiple times from the same group: the -3979 bp deletion was recovered from three of four mice for each group (0.5, 1.0, or 2.0 kJ/m<sup>2</sup>) of UVB-irradiated *p53*<sup>-/-</sup> mice. The complex types were recovered from four *p53*<sup>-/-</sup> mice irradiated with 1.0 kJ/m<sup>2</sup> UVB.

I and II). The most frequent point mutations in the epidermis of UVB-irradiated mice were G:C to A:T transitions induced at dipyrimidine sites, such as 5'-TC-3' and 5'-CC-3', which were 86–95% and 83–95% of total G:C to A:T transitions in UVB-irradiated *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> mice, respectively. From studies on UVB-irradiated *E. coli*, mammalian cells, and the *p53* gene in nonmelanoma skin cancer, it is known that UVB irradiation generates cyclobutane pyrimidine dimers (CPD) and pyrimidine(6-4)pyrimidine photoproducts (6-4PP) at dipyrimidine sites and induces G:C to A:T base substitutions [Miller, 1985; Hauser et al., 1986; Hsia et al., 1989; Brash et al., 1991; Ziegler et al., 1993; Daya-Grosjean et al., 1995]. The spectra of UVB-induced mutations in the epidermis of Muta<sup>TM</sup> mice were reported to be dominated by G:C to A:T transitions at dipyrimidine sites in the *lacZ* transgene [Ikehata et al., 2003]. The results in this study and previous reports suggest that UVB-induced photo-

products cause characteristic mutations at similar efficiencies in the epidermis of both *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> mice.

Interestingly, there were no increases in *gpt* MFs at UVB doses above 0.5 kJ/m<sup>2</sup> in both *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> mice (Fig. 1). These results are consistent with the previous observation that the *gpt* MF was increased about nine times by UVB irradiation at 0.3 kJ/m<sup>2</sup>, but did not significantly increase more at doses of 0.5–2.0 kJ/m<sup>2</sup> in wild-type *gpt* delta mice [Horiguchi et al., 1999]. These results suggest that *gpt* MFs in the epidermis are saturated at these doses. Ikehata also reported that UVB induction of mutations was suppressed in acute high-dose exposure to the epidermis using Muta<sup>TM</sup> mice [Ikehata and Ono, 2002]. The suppression occurred even in the absence of p53; therefore, it was not due to p53-dependent antimutagenic effects such as p53-dependent apoptosis. A higher efficiency of DNA repair might be induced at higher UVB doses, or highly

damaged cells might be selectively killed during inflammation induced by UVB irradiation [Ikehata and Ono, 2002]. Whatever the mechanisms are, our results (shown in Fig. 1) raise the possibility that factors other than *p53* contribute to genome stability in the murine epidermis.

UV-induced mutagenesis is induced by translesion DNA synthesis (TLS) that proceeds across UVB-induced photoproducts such as CPD or 6-4PP [Friedberg et al., 2006]. Specialized DNA polymerases involved in lesion bypass have been identified. These polymerases insert incorrect bases such as dGMP opposite the 3'C of CT sites at a relatively high frequency, thereby generating incorrect nascent DNA sequences during DNA synthesis [Prakash et al., 2005]. This process may rescue stalled DNA synthesis at the lesion and contribute to the completion of whole chromosome replication, but it may induce point mutations as byproducts. DNA polymerase iota, kappa, and zeta may be involved in the error-prone TLS across UV-induced photoproducts [Gueranger et al., 2008; Ziv et al., 2009]. These results shown in Figure 1 suggest that *p53* may not be involved in the error-prone TLS across UVB-induced lesions. Although the relationship between *p53* and TLS by specialized DNA polymerases has not been thoroughly examined, one report suggests that the mutations on plasmids carrying a benzo[*a*]pyrene-induced guanine adduct are suppressed by the presence of *p53* in mouse embryonic fibroblasts [Avkin et al., 2004]. In the experiments, the mutation frequencies on the plasmids were higher in cells derived from *p53*<sup>-/-</sup> mice than in cells from *p53*<sup>+/+</sup> mice. Therefore, it was concluded, that *p53* suppressed the error-prone nature of specialized DNA polymerases during the bypass processes. However, our results do not support this conclusion, because the MF and UVB-induced mutation spectra were similar between *p53*<sup>-/-</sup> and *p53*<sup>+/+</sup> mice. The apparent discrepancy may be due to different experimental conditions, for example, DNA lesions, cell types, and detection methods for mutations. Another possibility may be that higher induction of the *gpt* mutations in *p53*<sup>-/-</sup> mice could not be observed because the MFs were already saturated in both *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> mice with 0.5 kJ/m<sup>2</sup> irradiation. The effect of *p53* may be masked, due to a *p53*-independent saturation of *gpt* MFs in this study. Further investigation is needed to examine the relationship between *p53* and error rates of TLS by multiple specialized DNA polymerases.

In contrast to the *gpt* mutations, where no substantial differences were observed between *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> mice, Spi<sup>-</sup> MF in unirradiated *p53*<sup>-/-</sup> mice was 2.5 times higher than that in *p53*<sup>+/+</sup> counterparts, although there is no statistical significance because of the small number of *n* (Table III). Focusing on the specific mutation frequency, in unirradiated *p53*<sup>-/-</sup> mice, especially the specific mutation frequencies of large deletions and complex-type rearrangements were significantly higher than those of the large deletions in the *p53*<sup>+/+</sup> counterparts ( $1.58 \times 10^{-6}$  vs.  $0.17 \times 10^{-6}$ ,  $P = 0.04$ , Dunnett test) (Fig. 2).

These deletion and complex-type rearrangements are thought to be induced by nonhomologous end-joining during repair of DSB in DNA [Nohmi and Masumura, 2005]. The higher spontaneous mutation frequencies of large deletions and complex-type rearrangements in *p53*<sup>-/-</sup> mice suggests that the antigenotoxic effects of *p53* may be specialized to suppress the mutagenic end-joining process to seal DSB in DNA. This is consistent with previous reports that chromosome alterations, including chromosome loss/duplication and interstitial deletion, are more frequently observed in *p53*<sup>-/-</sup> mice compared with *p53*<sup>+/+</sup> mice [Shao et al., 2000]. Because of the antimutagenic effects, we expected that the specific Spi<sup>-</sup> mutation frequencies for large deletions and complex types would be significantly increased by UVB irradiation in *p53*<sup>-/-</sup> mice compared with *p53*<sup>+/+</sup> mice. However, the specific mutation frequencies did not increase more than the spontaneous level even after UVB irradiation at doses of 0.5, 1.0, or 2.0 kJ/m<sup>2</sup> in *p53*<sup>-/-</sup> mice (Fig. 2). The results suggest the *p53*-independent antimutagenic mechanisms that suppress *gpt* mutations (discussed earlier) may also act on cells that have DSB in DNA. Currently, the mechanisms are not known but may be related to inflammation in the skin induced by UVB irradiation [Ikehata and Ono, 2002]. Alternatively, *p53* may be positively involved in induction of deletions and complex-type mutations induced by UVB; therefore, there was no increase in the Spi<sup>-</sup> mutation frequency in UVB-irradiated *p53*<sup>-/-</sup> mice. It is reported that DSB in DNA are induced during the repair of UV photoproducts [Bradley and Taylor, 1981]. It is known that *p53* is involved in nucleotide excision repair (NER) [Ford and Hanawalt, 1995, 1997; Smith et al., 2000] and *p53* regulates the expression of several NER genes including *XPC* and *DDB2* [Hwang et al., 1999; Adimoolam and Ford, 2002]. Thus, *p53* may be involved in the induction of large deletions by regulating the repair of UVB photoproducts. If this is the case, Spi<sup>-</sup> large deletions will not be induced in *p53*<sup>-/-</sup> mice after UVB irradiation. However, it is possible that the small number of mice and the relatively high background mutation frequency may obscure an effect of UVB in *p53*<sup>-/-</sup> mice, because increase in the specific Spi<sup>-</sup> mutation frequency caused by UVB is very small even in *p53*<sup>+/+</sup> mice. To answer this issue, larger number of mice and improved experimental design may be needed.

The MFs of Spi<sup>-</sup> deletions in *p53*<sup>+/+</sup> mice increased twofold to fourfold when compared with the control level at UVB doses of 0.5, 1.0, or 2.0 kJ/m<sup>2</sup> (Table III). In a previous study, we observed suppression of UVB-induced large deletions at UVB doses of 1.0, 1.5, or 2.0 kJ/m<sup>2</sup>; therefore, the dose-response curve was a bell-shaped one [Horiguchi et al., 2001]. In this study, we did not observe such strong suppression of the Spi<sup>-</sup> MF at UVB doses of 1.0 and 2.0 kJ/m<sup>2</sup> (Fig. 2). The apparent discrepancy between the previous and current studies might be due to the different irradiation



tion conditions such as dose rates and UVB sources. The dose rate used in this study was 0.3 kJ/m<sup>2</sup>/min [5 J/m<sup>2</sup>/s], which is lower than that used in the previous study [17 J/m<sup>2</sup>/s]; although, total doses were similar. A handheld UV lamp in a cabinet was used in this study instead of the straight-tube fluorescent lights used in the previous study. The different wavelength distribution of UV from different lamps could also affect the dose responses. When we focus on the larger deletions (greater than 1 kb) and complex types, the specific Spi<sup>-</sup> MFs of *p53*<sup>+/+</sup> mice significantly increased, up to 5.5-fold higher than the control level at 2.0 kJ/m<sup>2</sup> ( $0.93 \times 10^{-6}$  vs.  $0.17 \times 10^{-6}$ ) (Fig. 2). However, the specific MF of large deletions and complex types was increased 17-fold in the previous study [Horiguchi et al., 2001]. The lower dose rate used in this study may have caused relatively weaker induction of larger deletions. Dose rate might be an important factor for UVB-induced large deletions driven by DSB and end-joining.

Thirty-nine Spi<sup>-</sup> large deletions (greater than 1 kb), recovered from both *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> mice, were sequenced and are shown in Figure 3. The majority of those deletions have short homologous sequences of 1–4 bp at the junction in both *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> mice. The largest deletion size identified was -7,094 bp. The Spi<sup>-</sup> mutation assays can detect a simultaneous inactivation of both the *gam* and *red* genes, which is usually induced by deletions. Because of the size limitation for lambda in vitro packaging reactions (there must be two cos sites separated by 38–51 kb of DNA), deletions up to 10 kb are detectable as Spi<sup>-</sup> mutations [Nohmi and Masumura, 2004, 2005]. Interestingly, an identical -3,979 bp deletion having a 4 bp (5'-TTTA-3') microhomology at the junction was repeatedly observed in both *p53*<sup>+/+</sup> and *p53*<sup>-/-</sup> mice. This deletion is not UV-dependent because the same deletion was also independently recovered from the unirradiated epidermis. In the previous study, the same deletion was also observed multiple times in both UVB-irradiated and UVB-unirradiated epidermis (six independent mutations were recovered from 12 mice) [Horiguchi et al., 2001]. In contrast, this deletion was not observed in other tissues, with the exception of 1 identified from the liver out of more than 400 independent Spi<sup>-</sup> mutants previously sequenced [Yatagai et al., 2002; Nohmi and Masumura, 2004]. This -3,979 bp Spi<sup>-</sup> deletion may be a hot spot mutation in the epidermis of the mouse. In human skin, a -3,895 bp deletion in mitochondrial DNA was proposed to be a marker for sunlight exposure [Krishnan et al., 2004]. It has a 12-bp microhomology at the junction (5'-CCATACCCCGAA-3'). The relationship between the -3,979 bp deletion in the chromosome DNA of the murine epidermis and the -3,895 bp deletion in the mitochondria DNA in human skin is currently unknown.

Several p53-deficient mouse strains were previously developed to investigate the function of p53 in mutagenesis

by in vivo mutation detection systems using *lacZ*, *lacI*, *aprt*, etc. [Morris, 2002]. Those mouse models have a common phenotype, a propensity to develop thymic lymphoma. However, the effect of p53 on spontaneous and mutagen-induced mutations has not been thoroughly investigated. In this study, we investigated the role of p53 in spontaneous and UV-induced mutations, including both point mutations and deletions, in the mouse epidermis. The results showed that p53 may suppress spontaneous deletions. This implies that once p53 is inactivated, the mutated cells will display high levels of genome instability, even without additional exposure to sunlight or other environmental mutagens. To better understand p53 functions in mutagenesis in vivo, it is important to further investigate how p53 is involved in several cellular functions such as DNA damage-response and repair pathways.

## REFERENCES

- Adams WT, Skopek TR. 1987. Statistical test for the comparison of samples from mutational spectra. *J Mol Biol* 194:391–396.
- Adimoolam S, Ford JM. 2002. p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. *Proc Natl Acad Sci USA* 99:12985–12990.
- Aubrecht J, Secretan MB, Bishop AJ, Schiestl RH. 1999. Involvement of p53 in X-ray induced intrachromosomal recombination in mice. *Carcinogenesis* 20:2229–2236.
- Avkin S, Goldsmith M, Velasco-Miguel S, Geacintov N, Friedberg EC, Livneh Z. 2004. Quantitative analysis of translesion DNA synthesis across a benzo[a]pyrene-guanine adduct in mammalian cells: The role of DNA polymerase kappa. *J Biol Chem* 279:53298–53305.
- Bradley MO, Taylor VI. 1981. DNA double-strand breaks induced in normal human cells during the repair of ultraviolet light damage. *Proc Natl Acad Sci USA* 78:3619–3623.
- Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten J. 1991. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. *Proc Natl Acad Sci USA* 88:10124–10128.
- Buettner VL, Hill KA, Nishino H, Schaid DJ, Frisk CS, Sommer SS. 1996. Increased mutation frequency and altered spectrum in one of four thymic lymphomas derived from tumor prone *p53*/Big Blue double transgenic mice. *Oncogene* 13:2407–2413.
- Cariello NF, Piegorsch WW, Adams WT, Skopek TR. 1994. Computer program for the analysis of mutational spectra: Application to *p53* mutations. *Carcinogenesis* 15:2281–2285.
- Daya-Grosjean L, Dumaz N, Sarasin A. 1995. The specificity of *p53* mutation spectra in sunlight induced human cancers. *J Photochem Photobiol B* 28:115–124.
- Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr., Butel JS, Bradley A. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. *Nature* 356:215–221.
- Ford JM, Hanawalt PC. 1995. Li-Fraumeni syndrome fibroblasts homozygous for *p53* mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. *Proc Natl Acad Sci USA* 92:8876–8880.
- Ford JM, Hanawalt PC. 1997. Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. *J Biol Chem* 272:28073–28080.
- Friedberg EC, Walker GC, Siede W, Wood RD, Schultz RA, Ellenberger T. 2006. DNA Repair and Mutagenesis. 2nd ed. Washington, DC: ASM press. 1118 p.

- Guengerer Q, Stary A, Aoufouchi S, Faili A, Sarasin A, Reynaud CA, Weill JC. 2008. Role of DNA polymerases eta, iota and zeta in UV resistance and UV-induced mutagenesis in a human cell line. *DNA Repair (Amst)* 7:1551–1562.
- Hauser J, Seidman MM, Sidur K, Dixon K. 1986. Sequence specificity of point mutations induced during passage of a UV-irradiated shuttle vector plasmid in monkey cells. *Mol Cell Biol* 6:277–285.
- Horiguchi M, Masumura K, Ikehata H, Ono T, Kanke Y, Sofuni T, Nohmi T. 1999. UVB-induced *gpt* mutations in the skin of *gpt* delta transgenic mice. *Environ Mol Mutagen* 34:72–79.
- Horiguchi M, Masumura K, Ikehata H, Ono T, Kanke Y, Nohmi T. 2001. Molecular nature of ultraviolet B light-induced deletions in the murine epidermis. *Cancer Res* 61:3913–3918.
- Hsia HC, Lebkowski JS, Leong PM, Calos MP, Miller JH. 1989. Comparison of ultraviolet irradiation-induced mutagenesis of the *lacI* gene in *Escherichia coli* and in human 293 cells. *J Mol Biol* 205:103–113.
- Hwang BJ, Ford JM, Hanawalt PC, Chu G. 1999. Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. *Proc Natl Acad Sci USA* 96:424–428.
- Ikehata H, Ono T. 2002. Mutation induction with UVB in mouse skin epidermis is suppressed in acute high-dose exposure. *Mutat Res* 508:41–47.
- Ikehata H, Aiba S, Ozawa H, Ono T. 2001. Thermolysin improves mutation analysis in skin epidermis from ultraviolet light-irradiated Muta mouse. *Environ Mol Mutagen* 38:55–58.
- Ikehata H, Masuda T, Sakata H, Ono T. 2003. Analysis of mutation spectra in UVB-exposed mouse skin epidermis and dermis: Frequent occurrence of C→T transition at methylated CpG-associated dipyrimidine sites. *Environ Mol Mutagen* 41:280–292.
- Ikehata H, Nakamura S, Asamura T, Ono T. 2004. Mutation spectrum in sunlight-exposed mouse skin epidermis: Small but appreciable contribution of oxidative stress-mediated mutagenesis. *Mutat Res* 556:11–24.
- Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. 1994. Tumor spectrum analysis in p53-mutant mice. *Curr Biol* 4:1–7.
- Krishnan KJ, Harbottle A, Birch-Machin MA. 2004. The use of a 3895 bp mitochondrial DNA deletion as a marker for sunlight exposure in human skin. *J Invest Dermatol* 123:1020–1024.
- Lambert IB, Singer TM, Boucher SE, Douglas GR. 2005. Detailed review of transgenic rodent mutation assays. *Mutat Res* 590:1–280.
- Miller JH. 1985. Mutagenic specificity of ultraviolet light. *J Mol Biol* 182:45–65.
- Morris SM. 2002. A role for p53 in the frequency and mechanism of mutation. *Mutat Res* 511:45–62.
- Nishino H, Knoll A, Buettner VL, Frisk CS, Maruta Y, Haavik J, Sommer SS. 1995. p53 wild-type and p53 nullizygous Big Blue transgenic mice have similar frequencies and patterns of observed mutation in liver, spleen and brain. *Oncogene* 11:263–270.
- Nohmi T. 2007. Novel DNA polymerases and novel genotoxicity assays. *Genes Environ* 29:75–88.
- Nohmi T, Masumura K. 2004. *Gpt* delta transgenic mouse: A novel approach for molecular dissection of deletion mutations in vivo. *Adv Biophys* 38:97–121.
- Nohmi T, Masumura K. 2005. Molecular nature of intrachromosomal deletions and base substitutions induced by environmental mutagens. *Environ Mol Mutagen* 45:150–161.
- Nohmi T, Katoh M, Suzuki H, Matsui M, Yamada M, Watanabe M, Suzuki M, Horiya N, Ueda O, Shibuya T, Ikeda H, Sofuni T. 1996. A new transgenic mouse mutagenesis test system using Spi<sup>-</sup> and 6-thioguanine selections. *Environ Mol Mutagen* 28:465–470.
- Nohmi T, Suzuki T, Masumura K. 2000. Recent advances in the protocols of transgenic mouse mutation assays. *Mutat Res* 455:191–215.
- Prakash S, Johnson RE, Prakash L. 2005. Eukaryotic translesion synthesis DNA polymerases: Specificity of structure and function. *Annu Rev Biochem* 74:317–353.
- Purdie CA, Harrison DJ, Peter A, Dobbie L, White S, Howie SE, Salter DM, Bird CC, Wyllie AH, Hooper ML. 1994. Tumour incidence, spectrum and ploidy in mice with a large deletion in the *p53* gene. *Oncogene* 9:603–609.
- Sands AT, Suraokar MB, Sanchez A, Marth JE, Donehower LA, Bradley A. 1995. p53 deficiency does not affect the accumulation of point mutations in a transgene target. *Proc Natl Acad Sci USA* 92:8517–8521.
- Shao C, Deng L, Henegariu O, Liang L, Stambrook PJ, Tischfield JA. 2000. Chromosome instability contributes to loss of heterozygosity in mice lacking p53. *Proc Natl Acad Sci USA* 97:7405–7410.
- Shibata A, Masutani M, Nozaki T, Kamada N, Fujihara H, Masumura K, Nakagama H, Sugimura T, Kobayashi S, Suzuki H, Nohmi T. 2003. Improvement of the Spi<sup>-</sup> assay for mutations in *gpt* delta mice by including magnesium ions during plaque formation. *Environ Mol Mutagen* 41:370–372.
- Smith ML, Ford JM, Hollander MC, Bortnick RA, Amundson SA, Seo YR, Deng CX, Hanawalt PC, Fornace AJ Jr. 2000. p53-mediated DNA repair responses to UV radiation: Studies of mouse cells lacking *p53*, *p21*, and/or *gadd45* genes. *Mol Cell Biol* 20:3705–3714.
- Tsukada T, Tomooka Y, Takai S, Ueda Y, Nishikawa S, Yagi T, Tokunaga T, Takeda N, Suda Y, Abe S. 1993. Enhanced proliferative potential in culture of cells from p53-deficient mice. *Oncogene* 8:3313–3322.
- Yatagai F, Kurobe T, Nohmi T, Masumura K, Tsukada T, Yamaguchi H, Kasai-Eguchi K, Fukunishi N. 2002. Heavy-ion-induced mutations in the *gpt* delta transgenic mouse: Effect of *p53* gene knockout. *Environ Mol Mutagen* 40:216–225.
- Ziegler A, Leffell DJ, Kunala S, Sharma HW, Gailani M, Simon JA, Halperin AJ, Baden HP, Shapiro PE, Bale AE. 1993. Mutation hotspots due to sunlight in the *p53* gene of nonmelanoma skin cancers. *Proc Natl Acad Sci USA* 90:4216–4220.
- Ziv O, Geacintov N, Nakajima S, Yasui A, Livneh Z. 2009. DNA polymerase zeta cooperates with polymerases kappa and iota in translesion DNA synthesis across pyrimidine photodimers in cells from XPV patients. *Proc Natl Acad Sci USA* 106:11552–11557.

Accepted by—  
J. Fuscoe

# Structural insight into dynamic bypass of the major cisplatin-DNA adduct by Y-family polymerase Dpo4

Jimson HY Wong<sup>1</sup>, Jessica A Brown<sup>2</sup>,  
Zucaí Suo<sup>2</sup>, Paul Blum<sup>3</sup>, Takehiko Nohmi<sup>4</sup>  
and Hong Ling<sup>1,\*</sup>

<sup>1</sup>Department of Biochemistry, University of Western Ontario, London, Ontario, Canada, <sup>2</sup>Department of Biochemistry, The Ohio State University, Columbus, OH, USA, <sup>3</sup>School of Biological Sciences, University of Nebraska, Lincoln, NE, USA and <sup>4</sup>Division of Genetics and Mutagenesis, National Institute of Health Sciences, Setagaya-ku, Tokyo, Japan

Y-family DNA polymerases bypass Pt-GG, the cisplatin-DNA double-base lesion, contributing to the cisplatin resistance in tumour cells. To reveal the mechanism, we determined three structures of the Y-family DNA polymerase, Dpo4, in complex with Pt-GG DNA. The crystallographic snapshots show three stages of lesion bypass: the nucleotide insertions opposite the 3'G (first insertion) and 5'G (second insertion) of Pt-GG, and the primer extension beyond the lesion site. We observed a dynamic process, in which the lesion was converted from an open and angular conformation at the first insertion to a depressed and nearly parallel conformation at the subsequent reaction stages to fit into the active site of Dpo4. The DNA translocation-coupled conformational change may account for additional inhibition on the second insertion reaction. The structures illustrate that Pt-GG disturbs the replicating base pair in the active site, which reduces the catalytic efficiency and fidelity. The *in vivo* relevance of Dpo4-mediated Pt-GG bypass was addressed by a *dpo4* knockout strain of *Sulfolobus solfataricus*, which exhibits enhanced sensitivity to cisplatin and proteomic alterations consistent with genomic stress.

The EMBO Journal (2010) 29, 2059–2069. doi:10.1038/emboj.2010.101; Published online 28 May 2010

Subject Categories: genome stability & dynamics; structural biology

Keywords: anti-cancer drug; cisplatin; DNA damage; translesion DNA synthesis; Y-family DNA polymerase

## Introduction

All living organisms are hindered by DNA damage that generates replication-blocking lesions in DNA. Therefore, there are DNA repair mechanisms to remove lesions and damage-tolerance mechanisms for replication through le-

sions. Translesion synthesis (TLS) is a DNA damage-tolerance mechanism that uses specialized DNA polymerases (e.g. members of the Y-family) to replicate damaged DNA (Friedberg *et al*, 2002; Lehmann, 2002). TLS has an important function in cell survival of DNA damage and is highly conserved from bacteria to humans (Goodman, 2002).

*cis*-Diamminedichloroplatinum (II) (cisplatin) is a widely used chemotherapeutic agent that covalently modifies DNA to block DNA replication in rapidly dividing tumour cells (Davidson *et al*, 1975; Lippert, 1999). Cisplatin reacts with the N7 atoms of adjacent guanine (G) bases to create a 1,2-intrastrand covalent linkage, *cis*-Pt-1,2-d(GpG) (Pt-GG) (Supplementary Figure S1), which is the major cisplatin adduct, representing ~65% of the cisplatin-DNA adducts in cells (Pinto and Lippard, 1985; Sherman *et al*, 1985; Coll *et al*, 1990; Takahara *et al*, 1995; Jamieson and Lippard, 1999). By inhibiting DNA synthesis, cisplatin-DNA adducts slow cell division, possibly activating programmed cell death or apoptosis (Eastman, 1990; Cohen and Lippard, 2001). Thus, cisplatin is an effective anti-cancer drug, especially for cancers of the testis, ovary, bladder, head, neck, and lung. TLS and DNA repair mechanisms have contributed to acquired and intrinsic cisplatin resistance, thereby limiting the drug's application and contributing to cancer recurrence (Siddik, 2003; Zorbas and Keppler, 2005). Cells have been shown to have the ability to replicate past cisplatin-DNA adducts (Gibbons *et al*, 1991; Mamenta *et al*, 1994; Vaisman *et al*, 1998). Some translesional DNA polymerases can bypass cisplatin-DNA adducts (Hoffmann *et al*, 1995, 1996; Vaisman and Chaney, 2000; Vaisman *et al*, 2000; Albertella *et al*, 2005) and are overexpressed in tumour cells (Canitrot *et al*, 1998; Bergoglio *et al*, 2001). In addition, TLS is increased in the drug-resistant cells (Gibbons *et al*, 1991; Mamenta *et al*, 1994), strongly suggesting that TLS is correlated with resistance to cisplatin (Richon *et al*, 1987; Gibbons *et al*, 1991; Roush *et al*, 1998). Thus, TLS is considered to be one of the main mechanisms of cisplatin resistance in cancer treatment (Vaisman *et al*, 1998; Suo *et al*, 1999).

Most of the specialized translesion DNA polymerases are members of the Y-family. These DNA polymerases have a spacious active site that can accommodate bulky and distorted DNA lesions (Yang and Woodgate, 2007). However, a result of the expansion of these enzymes' functional repertoire and substrate specificity is that Y-family DNA polymerases replicate DNA with a higher error frequency (McCulloch and Kunkel, 2008). Hence, although Y-family DNA polymerases promote damage tolerance and cell survival, they also contribute to enhanced cellular mutagenesis. Human Y-family DNA polymerase  $\eta$  bypasses Pt-GG in a relatively efficient and error-free manner (Vaisman *et al*, 2000; Albertella *et al*, 2005). Recently, a structural study on yeast DNA polymerase  $\eta$  ( $\gamma$ Pol $\eta$ ) in complex with Pt-GG DNA provides the first glimpse of Pt-GG lesion bypass during

\*Corresponding author. Department of Biochemistry, University of Western Ontario, London, Ontario, Canada N6A 5C1.  
Tel.: +1 519 661 3557; Fax: +1 519 661 3175;  
E-mail: hling4@uwo.ca

Received: 18 December 2009; accepted: 27 April 2010; published online: 28 May 2010

the base insertion stages (Alt *et al*, 2007). The canonical dCTP is the preferred nucleotide inserted by  $\gamma$ Pol $\eta$  opposite both the 3' and 5' G base of a Pt-GG cross-link (Alt *et al*, 2007). However, the structures do not show dCTP insertion opposite the 5' G base (Alt *et al*, 2007). Also notable, the  $\gamma$ Pol $\eta$  structures do not have the whole double-base Pt-GG adduct accommodated within the active site. Further study is essential to answer the key question of how the bulky/angular-shaped Pt-GG adduct is translocated through the active site of a DNA polymerase during the lesion bypass.

We report three crystal structures of a model Y-family DNA polymerase, DNA polymerase IV (Dpo4) from *Sulfolobus solfataricus*, in complex with Pt-GG DNA at 2.9, 1.9, and 2.0 Å resolution, respectively. During the TLS process, DNA polymerases perform two fundamental steps: nucleotide incorporation opposite the damaged DNA base(s) and extension past the lesion. Our three ternary structures encompassed these pertinent steps of TLS: dCTP insertion opposite the 3' and 5' G bases of the Pt-GG adduct and correct dATP insertion for the extension step immediately downstream of the lesion. To support the structural results, we have investigated the bypass of Pt-GG catalysed by Dpo4 in solution. In addition, the *in vivo* function of Dpo4 was addressed for the first time through the construction and analysis of a *S. solfataricus* cell line harbouring a loss of function mutation leading to deficiency of this organism's only lesion bypass polymerase.

## Results

### Overall structures of the Dpo4–DNA–dNTP ternary complexes

We have co-crystallized Dpo4 with template DNA containing Pt-GG with dNTPs against the 3' G (GG1), the 5' G (GG2) of Pt-GG, and the T base 5' to the lesion (GG3), respectively (Figure 1). All three of our Dpo4–Pt-GG–DNA–dNTP ternary structures (GG1, GG2, and GG3) share a common crystal form, with one complex per asymmetric unit (Table I). The overall ternary complexes are essentially identical to the type I complex and other active Dpo4 structures (Ling *et al*, 2001, 2003, 2004a, b). The type I structure is the first Dpo4–DNA–dNTP ternary complex structure with normal nucleotide incorporation and represents a common active form of Dpo4, as well as most other Y-family DNA polymerases (Supplementary Figure S2). In this common active form, the finger domain is in a closed conformation packing against the catalytic palm domain and contacts the replicating base pair in the active site. Structural superposition of the three complex structures and the type I shows that the Dpo4 remains an identical conformation with root mean square deviations (r.m.s.d.) <0.5 Å on all C $\alpha$  atoms, pair wisely. The closed finger conformation has been observed in other Dpo4 structures, which were solved in different crystal forms (Ling *et al*, 2004a; Rechkoblit *et al*, 2006; Wong *et al*, 2008). Therefore, the closed finger conformation in our current structures is independent of crystal packing.


All three GG complexes have the same 18-mer DNA template that contains a site-specific Pt-GG adduct at the 14th and 15th positions from the DNA's 3' end (Figure 2). Three different 13-mer primers were designed to generate DNA substrates for nucleotide insertions opposite or extension beyond the Pt-GG adduct in the template strand (Figure 2). Dideoxy-terminated primers (ddC or ddG) were

used to trap the ternary complexes in the desired reaction stages during TLS of Pt-GG. The single-stranded template residues 5' to the adduct are completely disordered in both insertion structures GG1 and GG2. The incoming nucleotides in the three GG complexes are superimposed well with the dNTP from the ternary complexes of Dpo4 and undamaged DNA (Figure 1D and E) (Ling *et al*, 2004a; Vaisman *et al*, 2005), showing that Dpo4 maintains the incoming dNTP in a similar position and orientation in the active site, regardless of the DNA template position. Thus, the structural differences are localized at the site of the DNA adduct in the template strand. The Pt-GG adduct conformation is varied in the three structures, which deviates from the low-energy Pt-GG conformation as described by the ideal torsion angles  $\alpha$  and  $\beta$  (Supplementary Table S1). The torsion angle  $\alpha$  defines the degree of Pt out-of-plane bending (C8–N7–C5–Pt, an ideal value of 180° for in-plane conformation), and  $\beta$  represents the torsion angle between the G base planes and the Pt-coordination plane (C8–N7–Pt–cisN, an ideal value of 90°) (Yao *et al*, 1994). The torsion angles in our three structures deviate up to 10° beyond the range established from the single *cis*-Pt-GG adduct crystal structures (Sherman *et al*, 1985) and the protein-free Pt-GG adducted DNA structures (Takahara *et al*, 1995), and thus are further off from the ideal low-energy state (Yao *et al*, 1994). The DNA helices bound by Dpo4 are in a straight form with bending angles <18° over the 12-bp helical region, which is in contrast to the curved protein-free Pt-GG adducted DNA (Takahara *et al*, 1995) (Figure 3). It seems that the helical DNA geometry and the protein binding place additional strains to distort the Pt-GG adduct from its low-energy conformations. The distances between the P $\alpha$  atoms of the incoming nucleotides and the C3' atoms at the 3' end of the primer strands are ~5 Å, a catalytically competent distance, in the presence of two catalytic divalent metal ions in all three structures (Figure 1).

### GG1: dCTP insertion opposite the 3' G of Pt-GG (first insertion)

The GG1 structure represents the first insertion stage of Pt-GG lesion bypass. The incoming dCTP is poised for insertion opposite the 3' G base of the Pt-GG adduct at the active site. The position of the platinum atom is identified by an anomalous difference peak, which is shifted into the DNA major groove (Figure 1A). Moreover, the finger domain in the closed conformation wedges between two Pt-coordinated G bases and blocks the 5' G from entering the active site completely (Figure 2A). Thus, the 5' base of Pt-GG is in close contact with the finger domain and is positioned outside of the active site. As the 3' G and 5' G are covalently linked through cisplatin, the 3' G base is dragged into the major groove by the 5' G, thereby preventing the 3' G from resting in the optimal template position of an undamaged DNA template (Figure 1). Compared with an undamaged DNA template, the 3' G is shifted 4.0 Å towards the major groove (Figure 1A, D, and E). The DNA helix in GG1 keeps a straight form, and the adduct is not completely included into the helical structure yet. In the first insertion structure (GG1), Pt-GG possesses a large roll angle of 135° between the 5' G and 3' G bases due to its close contacts with the finger domain (Figure 2A). In this open angular conformation, the Pt atom is out of plane of the bases with the  $\alpha$  angles deviated by 8–37°, and the Pt-





**Figure 1** The structures of the GG1 (A), GG2 (B), and GG3 (C) Dpo4–DNA–dNTP ternary complexes. The finger, palm, thumb, and little finger domains distinguished by their respective colours in (B). The Pt–GG lesioned template is represented in magenta, with the platinum atom shown as a cyan ball. The zoomed in boxes of the active site are covered with the Pt-anomalous maps ( $5\sigma$ ) in orange. The catalytic residues are shown in the middle panel of Figure 1C, which present invariantly in all three structures. There are two base conformers of Pt–GG in (B), with each Pt atom at 0.5 occupancy. The top views of the replicating base pairs are covered by a blue 2Fo–Fc maps contoured to  $1.0\sigma$  at 2.9, 1.9, and 2.0 Å resolution, respectively. The A–T pair in green sticks superimposed with GG1 (A) is taken from a Dpo4–DNA–dNTP complex structure (PDB: 1S00), which depicts the regular position of an undamaged purine–pyrimidine base pair in the Dpo4 active site. The grey nucleotide in (A, middle box) is a ghost model for the 3′ primer base that is disordered in GG1. The green spheres are  $Ca^{2+}$  ions. (D) A top view comparison of the GG1 (blue), GG2 (red), and GG3 (cyan) replicating base pairs with an undamaged pyrimidine–purine (T–A) replicating base pair (2AGQ, black). (E) A top view comparison of the Dpo4 GG1 base pair with the yeast pol  $\eta$  GG1 (2R8J, beige) and an undamaged purine–pyrimidine (A–T) (1S00, green) replicating base pairs.

coordination plane off the ideal  $\beta$  torsion by 22–60° (Supplementary Table S1). The conformation of Pt–GG in GG1 are dramatically distorted due to the position of the finger domain wedging between the two G bases. In contrast, the Pt–GG adducts in the open yPol $\eta$  structure are very close to the ideal model with roll angles of  $\sim 90^\circ$ ,  $\alpha$  angles of  $< 5^\circ$  from ideal  $180^\circ$ , and  $\beta$  angles within  $30^\circ$  from ideal  $90^\circ$  (Alt *et al*, 2007).

The Pt–GG adduct outside of the active site is not stabilized by base stacking and Watson–Crick (WC) base pairing,

leading to a disturbed template (poor density, Figure 1A) with high B-factors. The 3′G base of the Pt–GG adduct shifted into the major groove loses base stacking with the upstream –1 template base. Furthermore, the shifted 3′G base does not form a WC base pair with the incoming dCTP that is in the same position as the incoming dNTPs in the structures 2AGQ and 1S00 (Figure 1A, D, and E) which exhibit the regular position of an undamaged base pair in the Dpo4 active site (Ling *et al*, 2004a; Vaisman *et al*, 2005). Only one H-bond is maintained in the misaligned base pair, which is between two

**Table I** Data collection and refinement statistics

	GG1	GG2	GG3
<i>Data collection</i>			
Space group	P2 <sub>1</sub> 2 <sub>1</sub> 2	P2 <sub>1</sub> 2 <sub>1</sub> 2	P2 <sub>1</sub> 2 <sub>1</sub> 2
<i>Cell dimensions</i>			
<i>a</i> , <i>b</i> , <i>c</i> (Å)	98.6, 101.2, 52.4	98.2, 103.2, 52.3	99.2, 103.7, 52.0
Resolution (Å) <sup>a</sup>	50.0–2.90 (3.00–2.90)	50.0–1.93 (1.96–1.93)	50.0–2.00 (2.03–2.00)
<i>R</i> <sub>sym</sub> or <i>R</i> <sub>merge</sub>	0.061 (0.670)	0.066 (0.474)	0.087 (0.722)
<i>I</i> / $\sigma$ <i>I</i>	22.0 (2.2)	27.4 (2.35)	24.5 (2.5)
Completeness (%)	98.6 (99.4)	99.2 (91.6)	99.8 (95.3)
Redundancy	3.5 (3.4)	7.6 (5.3)	8.0 (6.2)
<i>Refinement</i>			
Resolution (Å)	45.0–2.90	27.6–1.93	29.0–2.00
No. of reflections	12009	40552	36729
<i>R</i> <sub>work</sub> / <i>R</i> <sub>free</sub>	0.285/0.309	0.243/0.261	0.224/0.235
<i>No. of atoms</i>			
Protein	2743	2728	2714
DNA	586	636	656
Ligand/ion	22	3	4
Water	49	307	258
<i>B-factors</i>			
Protein	60.4	32.8	34.0
DNA	76.3	34.1	38.7
Ligand/ion	58.8	26.1	36.8
Water	55.0	42.6	41.2
<i>R.m.s. deviations</i>			
Bond lengths (Å)	0.009	0.008	0.015
Bond angles (deg)	1.73	1.71	1.64

<sup>a</sup>Values in parentheses are for highest-resolution shell.


NH<sub>2</sub> groups from the 3'G base (N2) of Pt-GG and the base (N4) of dCTP (Figure 1A). Noticeably, the H-bond is a symmetrical H-bond that is of greater-than-normal strength (Cleland *et al*, 1998; Kraut *et al*, 2006; Lone *et al*, 2007). The symmetric H-bond is formed between donor and acceptor atoms from identical NH<sub>2</sub> groups that have equal pK<sub>a</sub> values (Supplementary Figure S1). The unique H-bond provides a structural basis for the preference of dCTP insertion opposite the lesion in the primer extension assays (see *In Vitro* Studies). Other bases, such as A, T, and G, do not have such a NH<sub>2</sub> group as found in C, to form a symmetrical and stronger H-bond with the major groove-shifted 3'G of Pt-GG in the GG1 structure. Therefore, dCTP is the preferred nucleotide incorporated at the 3'G of Pt-GG, despite the WC base pair being disrupted by the covalent modification of the DNA template base.

The structural perturbation within the DNA template strand is propagated to the 3' end of the primer strand at the template-primer junction. The template C base upstream (3') to the Pt-GG lesion loses the base stacking interaction with the 3'G and is over wound by 12° (Figure 2A). Consequently, the 3'G base of the primer as a base pairing partner for the over wound template C base is disordered as the electron density for the G base completely disappears (Figure 1A; Supplementary Figure S3). The disordered primer end likely causes template-primer misalignment, which leads to frameshift mutations. The disordering observed in GG1 is supported by a single deletion by Dpo4 in our solution studies (see *In vitro* Studies below). The incoming dCTP resides at a catalytically competent position with the distance between its P $\alpha$  and the 3' end of the primer being 5.6 Å (Figures 1A and 2A), as the backbone of the primer strand is still structured at its 3' end (Supplementary Figure S3). However, base stacking

interactions were lost between the incoming nucleotide and the disordered primer base, which makes the ternary complex less stable than the structures with undamaged DNA. The lesion template-induced disordering of 3' terminal primer end would contribute to the impaired catalytic capability of Dpo4 at this stage (see *In vitro* studies).

#### **GG2: dCTP incorporation against the 5'G of Pt-GG (second insertion)**

An incoming dCTP is inserted opposite the 5'G of Pt-GG in the GG2 ternary complex that captures the second insertion stage. For the first time, this structure shows the two G bases of Pt-GG entering a polymerase active site simultaneously (Figure 1B). The adduct is in two alternate conformations (GG2a and GG2b) that are tilted about 10° with respect to each other (Figures 2B, C, and 3A). In the anomalous difference map, two discrete peaks show the alternate positions of the Pt atom (Figure 1B). The presence of the alternate conformers agrees with the bulged electron density map around the Pt-GG adduct (Figure 3A). The DNA helix keeps a straight form as observed in other Dpo4–DNA complex structures (Figure 3B). As it translocated into the active site (Figure 2E), the adduct adopts depressed roll ( $\rho$ ) angles as low as 22° between the cross-linked bases, substantially less than ~90° roll angles observed in a single Pt-GG (Sherman *et al*, 1985). In other words, the roll angle is converted from 135° in GG1 to 22° in GG2 to fit Pt-GG into the active site (Figure 2E). Accordingly, the  $\alpha$  and  $\beta$  torsion angles of Pt-GG deviate up to 60° from the low-energy conformation (Supplementary Table S2). A reduction in the roll angles and use of alternate conformations make the cross-linked Pt-GG more compatible with the base stacking system of a straight helix (Figure 3B). This set-up




**Figure 2** Pt-GG adducts in the active sites of Dpo4 and ypo1η. All panels are close-up views of the enzyme active sites where the finger domain is in cyan. The platinum (Pt) atom is shown as a cyan ball. The DNA is shown as stick-balls, with the template strand in orange and the primer strand in yellow. The sequences of the template/primer DNA in the complexes are shown on the tops of panels (A–D), cross-linked G bases are in red. The arrows indicate the incoming dNTP positions. (A) GG1, where dCTP (pink) is paired opposite the 3'G of Pt-GG (dark pink). (B, C) GG2, two alternate conformations of GG2 (translucent pink, GG2a in (B), GG2b in (C)), where dCTP (pink) is paired opposite the 5'G of Pt-GG. (D) GG3, where dATP is paired with the T base that is 5' to the Pt-GG lesion. (E) Superposition of the GG1 (semi-transparent, left side) and GG2 (solid, right) structures of Dpo4, where DNA is shown as grey sticks with the 5'G of Pt-GG is in red with arrows, and the 3'G is in blue. The Pt-GG adduct is translocated in different positions and shows different conformations in the two structures. (F) Superposition of the same reaction stage complexes of ypo1η with the same colour scheme as (E). In ypo1η (F), the Pt-GG adduct remains in a similar position with the 5'G bases (red bases with an arrow) superimposed well in both reaction stages, no translocation of Pt-GG occurs.

reduces the perturbation caused by an angular adduct on the DNA helical structure and helps the lesion fit into the active site.

The 5'G of Pt-GG forms a WC base pair with the incoming dCTP in the active site (Figure 1B). The replicating base pair is in the regular position and superimposed well with the undamaged DNA replicating base pairs (Figure 1D). The finger domain is in contact with the replicating base pair (Figure 2B and C), which makes the 5'G base of Pt-GG less tilted from the base stacking system than the 3'G base (Figure 3A and B). The  $\alpha$ -phosphate of dCTP was 4.5 Å from the C3' atom of ddC at the 3' end of the primer strand, indicating that

the incoming nucleotide is poised for catalysis. The WC base paired replicating base pair explains the preference of dCTP over other dNTPs in the second insertion step (see *In Vitro* Studies). However, the alternate conformations and the geometric strain on the angular Pt-GG bases reflect a high energetic state for the GG2 complex, which contributes to the reduced nucleotide incorporation in the second insertion (Brown *et al*, 2008). Overall, the energetically unfavourable adduct conformation and the Pt-GG conformational conversion associated entropy cost may account for the lowest efficiency of nucleotide incorporation in the second insertion during the Pt-GG bypass (Brown *et al*, 2008).



**Figure 3** Pt-GG conformations and helical DNA structures in the presence or absence of Dpo4 enzyme. (A) Alternate conformations of Pt-GG in the GG2 structure. The alternate Pt atom corresponds to discrete bulges of electron density for the 1.9 Å 2Fo-Fc map contoured at 1 $\sigma$ . (B–D) Comparison of the DNA helices in GG2 (B), GG3 (C), and enzyme-free Pt-GG structure (D) (PDB: 1AIO). The Pt-GG in the enzyme-free DNA induces a bend in the DNA helix.

### GG3: nucleotide incorporation after the bypass of the Pt-GG adduct (extension step)

In the GG3 structure, the incoming dATP is base paired with the template T base 5' to the lesion, illustrating primer extension after the Pt-GG lesion (Figure 1C). The Pt-GG adduct is in a depressed conformation with roll angle of 26° to fit into the straight DNA helix in GG3 (Figures 1C and 2D). As the Pt-GG adduct has moved out of the active site in GG3, the adduct is less strained than the adduct in GG2. The  $\alpha/\beta$  torsion angles of Pt-GG in GG3 are a few degrees less distorted from the low-energy conformation than the lesion in GG2 (Supplementary Table S1). A single anomalous peak shows one position of the platinum atom with a well-defined lesion structure (Figure 1C). The replicating base pair exhibits normal WC base pairing in the active site and is superimposed well with the standard replicating base pair in Dpo4 (Figure 1D). The replicating base pair has the template T and dATP in plane, which is confined by the closed finger domain (Figure 2D). However, the base pair (5'G\*:C) beneath the replicating base pair is significantly disrupted due to the tilted orientation of the 5'G base from the angular Pt-GG (Figure 3C). The G base buckles 15° and propels 18° from the base pair partner C base (Figures 1C and 3C). The disturbed base pair is not in the active site as a replicating base pair, so the structural distortion appears to be less disruptive to DNA replication as in GG1 and GG2. The crosslinked G base 18° tilting from the template T base in the active site, however, does disturb the replicating base pair as a poor stacking partner (Figure 3C), which corresponds to the nucleotide incorporation reduction observed in the extension stage (Brown *et al*, 2008). Overall, the GG3 complex structure was similar to that of Dpo4 with undamaged DNA (Ling *et al*, 2001, 2003, 2004a, b; Vaisman *et al*, 2005), which maintains an ideal WC base pairing for the replicating base pair in the active site (Figure 1C). The DNA structural disturbance caused by Pt-GG in GG3 is mainly on the base pair which has moved out of the active site. Therefore, the


Pt-GG lesion would impair catalysis less in the extension than that in the insertion stages (Brown *et al*, 2008).

### In vitro studies of Pt-GG bypass by Dpo4

To examine Dpo4-mediated bypass of Pt-GG under conditions similar to crystal formation, we performed a running start assay with a short heteroduplex 10/18-mer at 23°C (Supplementary Figure S4). The template was modified at positions 14 and 15 with cisplatin, identical to the one used for crystallographic studies. There was significant accumulation of intermediate products (13- and 14-mers) corresponding to nucleotide incorporation opposite the two G bases of the Pt-GG adduct (13-mer is pre-first insertion, 14-mer is pre-second insertion), identical to the observation for the assays with longer substrates at 37°C (Brown *et al*, 2008). Thus, these results support our structural observations that the Pt-GG disturbs the replicating base pair in the active site in GG1 and GG2, which causes Dpo4 to pause during nucleotide incorporation opposite the Pt-GG adduct. Interestingly, the full product is 1 nt shorter in the lesion DNA than that of the undamaged DNA in the control panel (Supplementary Figure S4). The shorter product is likely caused by -1 frameshift mutation due to template-primer misalignment. The misalignment has been observed in the Dpo4 structures in which template-primer junctions are disturbed in the active site (Ling *et al*, 2001, 2004a; Bauer *et al*, 2007). The single deletion observed in our running start assay supports the template-primer junction instability caused by the Pt-GG adduct, such as the disordered 3' end primer end in GG1. The frameshift mutations has been also observed in Pt-GG replication by human DNA polymerase  $\eta$  *in vitro* (Bassett *et al*, 2002), which may be a common mechanism in TLS of Pt-GG.

To confirm that WC base pairing in the active site is disturbed by the Pt-GG lesion in solution, we performed the nucleotide incorporation assays using individual dNTP nucleotides (Figure 4). Less product formation was observed





**Figure 4** Specificity of Dpo4-mediated nucleotide incorporation was tested for the (A) GG1 (first insertion), (B) GG2 (second insertion), and (C) GG3 (extension) reaction stages with a dNTP (A, C, G, or T). M represents the marker for the primer strand. In each panel, nucleotide incorporation assays were terminated after 10 min for undamaged DNA (left) and after 60 min for Pt-GG DNA (right).


when Dpo4 was replicating cisplatin-DNA compared with undamaged DNA (Figure 4), supporting the structural disturbance of the replicating base pairs in the GG1, GG2, and GG3 structures. During Pt-GG lesion bypass, Dpo4 preferentially inserted a canonical dCTP opposite the Pt-GG lesion in the following order: dCTP  $\gg$  dATP  $>$  dTTP  $>$  dGTP (Figure 4), a preference that is identical to the earlier results conducted at 37°C with a longer DNA substrate (Brown *et al*, 2008). These results are consistent with the structures in which the replicative base pair is either in a WC base pair (GG2) or in a misaligned WC base pair with a strong and symmetric H-bond (GG1). Interestingly, the dCTP misincorporation appears more pronounced than other dNTP misincorporations in Pt-GG adducted DNA replication (Figure 4, right panels). The dCTP mismatches are shown as a strong band in the extension (Figure 4C) and extra bands after two insertions

(Figure 4A and B). The pronounced C base mismatches are likely associated with the unstable replicating base pairs in the lesion DNA structures, which increases the probability of template-primer misalignment. Template-primer misalignment is sequence dependent (Ling *et al*, 2004a; Garcia-Diaz and Kunkel, 2006; Bauer *et al*, 2007), thus, a two G base lesion, such as Pt-GG, in the template may promote pronounced C misincorporation specifically.

Earlier kinetic studies have suggested that two distinct populations appear during nucleotide incorporation against the 3'G and 5'G of the Pt-GG lesion by Dpo4 (Brown *et al*, 2008). We confirmed that two distinct kinetic populations also existed with Dpo4 by performing similar kinetic assays with short primer-template DNA at room temperature (data not shown). Biphasic kinetics is consistent with the multiple conformations and mobility of the DNA substrate observed in the GG1 and GG2 structures.

#### *In vivo* studies of Pt-GG bypass

TLS by the human Y-family enzymes is a putative mechanism of intrinsic cisplatin resistance (Rabik and Dolan, 2007). However, the overlapping functions among the 16 human DNA polymerases complicate the contribution by Y-family DNA polymerases (Shachar *et al*, 2009). *S. solfataricus* is an ideal model organism, as it encodes only one Y-family DNA polymerase, Dpo4, which has TLS function *in vitro*. To better understand how a Y-family enzyme participates in the mechanism of drug resistance, we constructed a *dpo-4* knockout mutant of *S. solfataricus* by targeted gene disruption as described earlier (Worthington *et al*, 2003; Schelert *et al*, 2004) and characterized the consequence of Dpo4 deficiency. The *dpo-4* chromosomal mutation was confirmed using PCR to show that the mutant strain carried a disrupted *dpo-4* allele due to *lacS* gene insertion; and by western blot analysis to show the absence of detectable levels of Dpo4 in cell extracts (Supplementary Figures S5 and S6). Physiological studies that compared the *dpo-4* mutant with its otherwise isogenic wild-type parent were conducted and showed that Dpo4 was not essential for life as the growth rate, cell yield, efficiency of plating, and cell morphology were all normal in the *dpo-4* mutant strain (data not shown). These data also indicate that Dpo4 did not contribute substantially to replicative synthesis of the chromosome. However, chemical challenge using cisplatin reveals that Dpo4 deficiency elicited significant biological effects. To directly evaluate the *in vivo* function of Dpo4 towards cisplatin, a dose-response study was conducted using both the wild-type and *dpo-4* disruption mutant cell lines. The 50% lethal concentration (LC<sub>50</sub>) values of cisplatin were 23 µg/ml for the wild-type and 16 µg/ml for the *dpo-4* mutant (Supplementary Figure S7). The reduction in LC<sub>50</sub> dose of cisplatin in the *dpo-4* strain shows that Dpo4 has a significant function in the tolerance of cisplatin. Proteomic analysis revealed that Dpo4 deficiency perturbed the abundance of many proteins (Figure 5; Supplementary Table S2). For example, proteins with increased abundance in the *dpo-4* mutant include peptidyl-prolyl isomerase (SSO0758), fibrillarlin (SSO0940), and single-stranded DNA binding protein (SSO2364). Together, increased abundance of these proteins suggests that Dpo4 deficiency elicits some form of genomic stress and is consistent with heightened sensitivity to cisplatin drug challenge.



**Figure 5** Analysis of wild-type and *dpo-4* mutant proteomes. Proteins from cell extracts prepared from exponentially growing cell lines, were fractionated by 2D SDS-PAGE and their identities were determined by tandem MS/MS sequencing of peptides derived by trypsin hydrolysis, with subsequent matching to the *S. solfataricus* genome sequence. Values for isoelectric point (pI) and mass (MW) are indicated across the top and sides of the figure, respectively. Proteins with increased abundance in the *dpo-4* mutant are circled in the *dpo-4* panel; proteins with decreased abundance are circled in the wild-type panel. Proteins are numbered in correspondence with Supplementary Table S2.

## Discussion

### Structural snapshots capture unique Pt-GG conformational transitions in an active Y-family polymerase

Our structures provide the first complete picture of how a Y-family DNA polymerase traverses the two G bases of a Pt-GG cross-link and catalyses primer extension beyond the damaged site. The adduct in the template strand is shown in three distinct positions relative to the incoming nucleotide at the active site, clearly illustrating the translocation of the lesion template during bypass. Particularly, all three DNA-bound Dpo4 structures are in a common closed conformation in which the finger, thumb, and little finger domains grip DNA tightly (Ling *et al*, 2001; Nair *et al*, 2006; Lone *et al*, 2007; Kirouac and Ling, 2009). Interestingly, Pt-GG undergoes significant conformational changes, as it travels through the active site from GG1 to GG3. With the conformational change, the 5'G base of Pt-GG is able to enter into the active site in GG2 and GG3, which have the entire double-base adduct accommodated in a straight DNA helix. The unique conformational change of Pt-GG is not observed in the earlier *ypol* $\eta$  structures (Figure 2F) (Alt *et al*, 2007). The second insertion *ypol* $\eta$  structure with dATP does not translocate the 5'G into its active site and keeps the Pt-GG adduct in similar conformations and positions in both insertion stages (Figure 2F). In addition, our structures with an extension stage further highlight the importance of the depressed Pt-GG conformation to the DNA helix in the productive ternary complexes after the first insertion.

### Unique mechanism for double-base lesion bypass

The Pt-GG bypass differs from the only other double-base bypass in complex with Dpo4 for the *cis-syn* cyclobutane pyrimidine dimer lesion (CPD, TT dimer). For CPD lesion bypass, the entire TT dimer enters Dpo4's active site during the two-stage bypass, without conformational changes occurring in the dimer (Ling *et al*, 2003). The rigid and compact nature of the CPD allows Dpo4 to accommodate the entire

double-base lesion in the active site for both insertion stages. In Pt-GG bypass, Dpo4 has to alter the conformation of the adduct to accommodate the Pt-GG adduct in its active site. The structural differences reflect the varying catalytic efficiencies of Dpo4 bypassing different double-base lesions at the two insertion stages. Dpo4 bypasses the 5'T (second insertion) more efficiently than the 3'T (first insertion) because the double-base lesion does not fit the 'closed off' the active site well at the first insertion stage (Ling *et al*, 2003). In contrast, the insertion efficiency at the second insertion in Pt-GG bypass is much lower (180-fold) than the first insertion (Brown *et al*, 2008). The structural basis for lower dCTP incorporation against the 5'G at the second insertion would be strong geometric strains on the adduct when the angular adduct moves into the active site and the translocation-coupled conformational conversion, which is likely to be entropically costly. Thus, TLS for different double-base lesions catalysed by the same enzyme occurs through different bypass mechanisms, as revealed by the structural analyses.

Of the human Y-family enzymes, *pol* $\eta$  bypasses cisplatin-DNA adducts error freely while *pol* $\kappa$  performs error-prone TLS across Pt-GG (Bassett *et al*, 2003; Shachar *et al*, 2009). Human *pol* $\kappa$  keeps a similar closed conformation on the finger domain as Dpo4 and other mammalian Y-family polymerases (Supplementary Figure S2). A *pol* $\eta$  structure is only available from the yeast homologue (Alt *et al*, 2007), in which the finger domain is 16° open from the common closed conformation. The open conformation of *ypol* $\eta$  seems unable to translocate the Pt-GG adduct within the active site (Figure 1D). Moreover, based on steady-state kinetic data, the extension step for *hpol* $\eta$  is more difficult than Dpo4 in the incorporation opposite the lesion (Bassett *et al*, 2003), which is different from Dpo4 that has lowest replication efficiency at the second insertion. This discrepancy may be caused by structural differences observed in the two polymerases. The open conformation of *ypol* $\eta$  does not confine the entire adduct into the active site (Alt *et al*, 2007), which may affect the extension step. A recent study suggested that multiple polymerases participate in the bypass of Pt-GG in mammalian

cells, in which Y-family polymerases, such as pol $\eta$ , pol $\kappa$ , insert nucleotides opposite the lesion, and a B-family polymerase  $\zeta$  extends the primer after insertion to the lesion (Shachar *et al*, 2009). The slow extension step by hpol $\eta$  may be remedied by hpol $\zeta$  in mammalian cells.

### The mobile adducts destabilize the replicating base pair

Earlier biphasic kinetic data support that the Dpo4-DNA complex exists as at least two distinct populations (Brown *et al*, 2008). Pt-GG in different structural environments adopts different conformations with varied roll angles and  $\alpha/\beta$  torsion angles (Sherman *et al*, 1985; Takahara *et al*, 1995; Ohndorf *et al*, 1999). The two guanine bases in the *cis*-Pt(NH $_3$ ) $_2$ [d(pGpG)] (a single Pt-GG) crystal structure has a perpendicular conformation with a roll angle of  $\sim 90^\circ$  and  $\alpha/\beta$  angles differ from the ideal values in a narrow range of 5–30° (Sherman *et al*, 1985). When a Pt-GG adduct is incorporated in the middle of a duplex DNA, the roll angle is compressed to 30°, with the torsion angles  $\alpha/\beta$  deviated from ideal values up to 50° in protein-free adducted DNA helix (Takahara *et al*, 1995). The distorted and angular Pt-GG causes the 12-base pair duplex bending to a 43° curve (Figure 3D; Takahara *et al*, 1995). In GG2 and GG3, the DNA helices are straight with bending angle  $< 18^\circ$  over a 12-bp helical region, which further compresses the Pt-GG adduct with roll angle as low as 22° (Figure 3B and C). The Pt-GG adduct is distorted with the  $\alpha/\beta$  torsion angles up to 60° to fit into the active site and helical DNA, 10° more distortion than the ones observed in the Pt-GG adducts in protein-free DNA (Takahara *et al*, 1995). The  $\alpha/\beta$  torsion angles in the Dpo4 complexes are energetically unfavourable based on the molecular simulation (Yao *et al*, 1994). Particularly, the additional depression on the roll angle is reinforced by the close contact of the finger domain on the replicating base pair in GG2 (Figure 2B and C). The depression, combined with alternate conformations, brings the adduct to nearly parallel conformations in GG2 (Figure 3B). The geometric strains from the distortion would bring the adduct to a high-energy state that takes alternate conformations in GG2. Overall, Pt-GG is highly mobile in the two insertion structures due to its solvent exposure (GG1) and geometric strains (GG2). A similar mobile Pt-GG adduct also exists in the cisplatinated nucleosome structure where the intrastrand platinum adducts are packed into helical DNA (Wu *et al*, 2008). At 3.4 Å resolution, elongated Pt-anomalous density indicates the inherent mobility of the platinum atom covalently bonded to the parallel purine bases, which contrasts with the spherical anomalous selenium peaks in the same structure (Wu *et al*, 2008).

In summary, destabilization of the adduct perturbs the DNA structure, so that catalytic efficiency and fidelity are reduced in Dpo4-mediated bypass of Pt-GG (Brown *et al*, 2008). The misaligned G\*:dCTP in GG1 and alternate G\*:dCTP base pair in GG2 make replicating base pairs unstable, which would increase the probability of mutations and decrease the populations of the productive complexes of Dpo4-DNA. The mobility is consistent with the following observations in solution: (1) the pronounced C base misincorporation in the primer extension assays (Figure 4); (2) 72- and 860-fold reduction in incorporation efficiency ( $k_p/K_d$ ) at the first and second insertion steps, respectively, and six-fold reduction at the extension step, relative to control

undamaged DNA (Brown *et al*, 2008); and (3) two orders of magnitude of fidelity reduction in Pt-GG adducted DNA replication compared with undamaged DNA replication by Dpo4 (Brown *et al*, 2008). Interestingly, the symmetric H-bonding in the misaligned G\*:dCTP at the first insertion (GG1) and WC H-bonding in the second insertion (GG2) still provide specificity for selective dCTP incorporation against the Pt-GG lesion though enhanced misincorporation occurs in the disturbed base pairing environment.

## Conclusions

This work provides a new molecular model for TLS over DNA lesions. Our structures reveal that Pt-GG bypass is a unique, dynamic process in which the Pt-GG adduct undergoes conformational changes, as it is translocated through the 'close-off' active site of the Y-family polymerase. The angular double-base lesion adopts a depressed conformation to fit into the active site and the helical structure of DNA during the second insertion and extension stages. The incompatibility of angular adducts with helical DNA structure and the rigid active site, along with the stress caused by the depressed conformation, make the Pt-GG adduct energetically unfavourable conformations. The disturbed and deformed DNA template leads to instability of the replicating base pair, resulting in low replication efficiency and reduced fidelity during Pt-GG bypass. Particularly, in the second insertion, the entropically costly conformational conversion may additionally impede nucleotide incorporation against the 5'G of Pt-GG. The *in vivo* observations support that the Y-family polymerase Dpo4 has an important function in tolerance of cisplatin, implicating possible contributions of Y-family polymerases to cisplatin resistance. The knowledge of how platinum cross-linked lesions are replicated by a Y-family DNA polymerase may help the development of cross-linking platinum agents for cancer therapy.

## Materials and methods

### Protein purification, DNA preparation, and crystallization

Dpo4 was expressed and purified as described earlier (Ling *et al*, 2001). DNA oligonucleotide preparation was similar to that in the earlier reported work (Brown *et al*, 2008). A hanging drop vapor diffusion method was used to grow crystals of the Dpo4-DNA-dNTP ternary complex by using our earlier conditions with some modifications (Bauer *et al*, 2007). The detailed procedures are reported in the Supplementary data.

### Data collection and structure determination

Diffraction data for the GG1, GG2, and GG3 crystals were collected at beamline 24-ID-C (Argonne National Laboratory, IL) and processed using DENZO and SCALEPACK (Otwinowski and Minor, 1997). All crystal structures were solved with molecular replacement program PHASER (McCoy *et al*, 2005), with the type I structure as search model (PDB: 1JX4). Iterative cycles of simulated annealing, positional refinement, and B-factor refinement were performed using CNS (Brunger *et al*, 1998), along with manual rebuilding of the model using the graphics program COOT (Emsley and Cowtan, 2004). The GG1, GG2, and GG3 structures were refined to 2.9, 1.9, and 2.0 Å resolution, respectively.

### In vitro assays

All the *in vitro* assays were carried out as described earlier (Brown *et al*, 2008; Wong *et al*, 2008), with reaction temperature at 23°C. The detailed procedures are reported in the Supplementary data.

### Construction of the *S. solfataricus* dpo-4 mutant

The *dpo-4* knockout mutant of *S. solfataricus* was constructed as described earlier (Worthington *et al*, 2003; Schelert *et al*, 2004). The detailed procedures are reported in the Supplementary data.

### Molecular biology and proteomic methods

DNA cloning, DNA sequencing, PCR, and plasmid transformation of *Escherichia coli* were performed as described (Rockabrand *et al*, 1998; Rolfmeier *et al*, 1998; Haseltine *et al*, 1999). DNA concentrations were measured using a DyNA Quant 200 fluorometer (Hoefer). Protein concentrations were measured using the BCA Protein Assay Reagent Kit (Pierce). Chemiluminescent western blot analysis using anti-Dpo4 polyclonal sera was performed using the ECL system (Amersham Biosciences) as described (Rockabrand *et al*, 1998). Proteins were fractionated by two-dimensional SDS-PAGE as described (Hajduch *et al*, 2005). Protein samples were prepared using 50 ml of mid-exponential phase cultures collected by centrifugation at 3000g for 15 min at 26°C. Pelleted cells were extracted as described (Hajduch *et al*, 2005) and protein was precipitated for 1 h by exposure to five volumes of ice-cold 0.1 M ammonium acetate in 100% methanol at 22°C. Proteins were sequenced using tandem mass spectrometry (MS/MS) and peptides were identified by local BLAST against the *S. solfataricus* proteome as described (Worthington *et al*, 2003). Confirmed hits required a threshold peptide matching value (N) of at least five.

### In vivo cisplatin assay

Cell lines were cultured at 80°C with aeration in a minimal salts medium (Allen, 1959), at pH 3.0 with tryptone 0.2% (wt/vol) as sole carbon and energy source. Growth was monitored at a wavelength of 540 nm using a Cary 50 spectrophotometer (Varian).

## References

- Albertella MR, Green CM, Lehmann AR, O'Connor MJ (2005) A role for polymerase eta in the cellular tolerance to cisplatin-induced damage. *Cancer Res* 65: 9799–9806
- Allen MB (1959) Studies with Cyanidium caldarium, an anomalously pigmented chlorophyte. *Arch Mikrobiol* 32: 270–277
- Alt A, Lammens K, Chiocchini C, Lammens A, Pieck JC, Kuch D, Hopfner KP, Carell T (2007) Bypass of DNA lesions generated during anticancer treatment with cisplatin by DNA polymerase eta. *Science* 318: 967–970
- Bassett E, Vaisman A, Havener JM, Masutani C, Hanaoka F, Chaney SG (2003) Efficiency of extension of mismatched primer termini across from cisplatin and oxaliplatin adducts by human DNA polymerases beta and eta *in vitro*. *Biochemistry* 42: 14197–14206
- Bassett E, Vaisman A, Tropea KA, McCall CM, Masutani C, Hanaoka F, Chaney SG (2002) Frameshifts and deletions during *in vitro* translesion synthesis past Pt-DNA adducts by DNA polymerases beta and eta. *DNA Repair (Amst)* 1: 1003–1016
- Bauer J, Xing G, Yagi H, Sayer JM, Jerina DM, Ling H (2007) A structural gap in Dpo4 supports mutagenic bypass of a major benzo[a]pyrene dG adduct in DNA through template misalignment. *Proc Natl Acad Sci USA* 104: 14905–14910
- Bergoglio V, Canitrot Y, Hogarth L, Minto L, Howell SB, Cazaux C, Hoffmann JS (2001) Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents. *Oncogene* 20: 6181–6187
- Brown JA, Newmister SA, Fiala KA, Suo Z (2008) Mechanism of double-base lesion bypass catalyzed by a Y-family DNA polymerase. *Nucleic Acids Res* 36: 3867–3878
- Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL (1998) Crystallography & NMR system: a new software suite for macromolecular structure determination. *Acta Crystallogr D Biol Crystallogr* 54: 905–921
- Canitrot Y, Cazaux C, Frechet M, Bouayadi K, Lesca C, Salles B, Hoffmann JS (1998) Overexpression of DNA polymerase beta in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs. *Proc Natl Acad Sci USA* 95: 12586–12590
- Cleland WW, Frey PA, Gerlt JA (1998) The low barrier hydrogen bond in enzymatic catalysis. *J Biol Chem* 273: 25529–25532
- Cohen SM, Lippard SJ (2001) Cisplatin: from DNA damage to cancer chemotherapy. *Prog Nucleic Acid Res Mol Biol* 67: 93–130

Cisplatin was prepared as fresh aqueous solutions (2 mg/ml) before use and was added at early logarithmic phase.

### Coordinates

The atomic coordinates and structure factors have been deposited in the Protein Data Bank, <http://www.rcsb.org>, with accession codes 3M9M, 3M9N, and 3M9O for the structures GG1, GG2, and GG3, respectively.

### Supplementary data

Supplementary data are available at *The EMBO Journal* Online (<http://www.embojournal.org>).

## Acknowledgements

This work was supported by the Terry Fox Foundation (NCIC-015411) to HL. JAB was supported by an International PEO Scholar Award. ZS was supported by the National Science Foundation Career Award (MCB-0447899). PB is supported by National Institutes of Health (NIGMS 1R01GM090209-01). TN is supported by the Ministry of Education, Culture, Sports, Science, and Technology, Japan (MEXT, 18201010). We thank the staff at 24-ID of APS in Argonne National Laboratory for beamline support. TN thanks Masami Yamada and Mariarita De Felice for DNA constructs. PB thanks Karl Dana and Edith Soo for mutant analysis. We thank Dr Lynn Weir for critical reading of the paper.

## Conflict of interest

The authors declare that they have no conflict of interest.

- Coll M, Sherman SE, Gibson D, Lippard SJ, Wang AH (1990) Molecular structure of the complex formed between the anticancer drug cisplatin and d(pGpG): C222(1) crystal form. *J Biomol Struct Dyn* 8: 315–330
- Davidson JP, Faber PJ, Fischer Jr RG, Mansy S, Peresie HJ, Rosenberg B, VanCamp L (1975) 'Platinum-pyrimidine blues' and related complexes: a new class of potent antitumor agents. *Cancer Chemother Rep* 59: 287–300
- Eastman A (1990) Activation of programmed cell death by anticancer agents: cisplatin as a model system. *Cancer Cells* 2: 275–280
- Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr* 60: 2126–2132
- Friedberg EC, Wagner R, Radman M (2002) Specialized DNA polymerases, cellular survival, and the genesis of mutations. *Science* 296: 1627–1630
- Garcia-Diaz M, Kunkel TA (2006) Mechanism of a genetic glissando: structural biology of indel mutations. *Trends Biochem Sci* 31: 206–214
- Gibbons GR, Kaufmann WK, Chaney SG (1991) Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells. *Carcinogenesis* 12: 2253–2257
- Goodman MF (2002) Error-prone repair DNA polymerases in prokaryotes and eukaryotes. *Annu Rev Biochem* 71: 17–50
- Hajduch M, Ganapathy A, Stein JW, Thelen JJ (2005) A systematic proteomic study of seed filling in soybean. Establishment of high-resolution two-dimensional reference maps, expression profiles, and an interactive proteome database. *Plant Physiol* 137: 1397–1419
- Haseltine C, Montalvo-Rodriguez R, Carl A, Bini E, Blum P (1999) Extragenic pleiotropic mutations that repress glycosyl hydrolase expression in the hyperthermophilic archaeon *Sulfolobus solfataricus*. *Genetics* 152: 1353–1361
- Hoffmann JS, Pillaire MJ, Garcia-Estefania D, Lapalu S, Villani G (1996) *In vitro* bypass replication of the cisplatin-d(GpG) lesion by calf thymus DNA polymerase beta and human immunodeficiency virus type I reverse transcriptase is highly mutagenic. *J Biol Chem* 271: 15386–15392
- Hoffmann JS, Pillaire MJ, Maga G, Podust V, Hubscher U, Villani G (1995) DNA polymerase beta bypasses *in vitro* a single d(GpG)-cisplatin adduct placed on codon 13 of the HRAS gene. *Proc Natl Acad Sci USA* 92: 5356–5360